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ABSTRACT 
 
Screening extracts of indigenous South African plants for the presence of anti-
cancer compounds. 
 
MSc. thesis, Department of Biotechnology, Faculty of Science, University of the 
Western Cape 
  
Early man dabbled with the use of plant extracts to cure ailments. This practice has 
been passed down from generation to generation and today more than 50 % of the 
worlds’ drugs are natural products or derivatives thereof. Scientists have thus 
established a branch of research called natural product research. This branch of 
research involves the identification and purification of secondary metabolites with a 
specific biological activity. The methodology involves the screening of plant products 
for a specific biological activity, purification of the biologically active natural product 
by separation technology and structure determination. The biologically active natural 
product/s is then further scrutinized to serve as a novel drug or lead compound for the 
development of a novel drug.  
 
This research exploited this research methodology. I screened nine indigenous South 
African plants for anti-cancer 'pro-apoptotic' activity chosen on the basis of 
cytotoxicity and well-known ethno-medicinal value. It has been documented that 
choosing plants to be screened on this basis provides an increased possibility of 
finding biologically active compounds. The nine plants screened were Cotyledon 
 III 
orbiculata, Oxalis pes caprae, Echium plantagineum, Cissampelos capensis, 
Euphobia mauritanica, Haemanthus pubescens, Cynanchum africanum, Lessertia 
frutescens and Elytropappus rhinocerotis.  Their extracts were screened via the 
cytotoxicity assay and numerous apoptosis assays namely; the APOPercentageTM 
assay, Annexin V-PE Detection assay, Active Caspase-3 Detection assay and the 
APO-DIRECTTM Kit. E. rhinocerotis is the only extract that exhibited significant pro-
apoptotic activity in all of three cell lines (MCF7, HeLa and CHO) used. It is for this 
reason that this plant had been selected for further study.  
 
Anti-cancer activities associated with E. rhinocerotis plant extracts from different 
geographical locations were then assessed to ascertain the superlative extract to be 
used for the purification process. The aqueous extract from the E. rhinocerotis 
collected from Tulbagh in the Western Cape displayed the highest activity. The 
significant variation in pro-apoptotic activity induced by the same plant from 
different geographical locations may be a consequence of environmental variation or 
genetic variation. Thus, this study shows preliminary data that suggest a possible link 
between variation in apoptosis activity and genetic variation.  
 
The secondary metabolites in the extract from the E. rhinocerotis collected from 
Tulbagh were then purified by bio-activity guided fractionation. The fractionation or 
separation technology used includes organic extraction, Liquid Column 
Chromatography (LCC), Thin Layer Chromatography (TLC) and High Performance 
Liquid Column Chromatography (HPLC). The success of this purification process 
was monitored and ascertained by serial dilution assays of the active fraction after 
 IV 
each fractionation step. This process successfully transformed a complex mixture of 
secondary metabolites represented by numerous peaks on a chromatograph to a single 
peak. This warranted an attempt at structure determination by MS and NMR.  
 
NMR data allowed the elucidation of a partial structure. However, further purification 
is necessary for the elucidation of two side chains. Once these side chains are known, 
the pro-apoptotic activity of this compound (if novel) or commercially available 
compound must be verified. 
 
This research established that this research methodology is successful and provides 
optimism for the development of an anti-cancer drug. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1) Introduction 
 
Reflection and Wisdom! Can wisdom exist without reflection? The wise reflect on the 
past to ensure that the mistakes of the past do not recur, so too, do they reflect upon 
its milestones that serve as the building blocks of the future. Accordingly, we will 
visit the past and find wisdom in the practices of the ancestors. Traditionally 
indigenous plant species and their extracts were the primary source of medicine. 
Today, natural products or derivatives thereof constitute more that 50% of 
internationally approved therapeutic remedies (Cannell, 1998). It is therefore highly 
probable that these traditional medicines contain useful substances with unexplored 
medicinal properties. Of interest, are the plants medicinal values to one of the worlds 
leading causes of death, cancer! 
 
Cancer is a genetic disease characterized by uncontrolled cell growth in the absence 
of cell cycle regulation. Aberrant cell cycle regulation can arise as a consequence of 
DNA damage. Under normal physiological conditions the uncontrolled growth of 
damaged cells is restricted by apoptosis. However these cells can escape the 
regulatory mechanisms of apoptosis as a result of secondary mutations to genes that 
regulate apoptosis. This DNA damage can be a result of several environmental factors 
such as stress, smoking, pollution, diet, toxins and endogenous processes such as 
errors in replication of DNA and chemical instability of certain DNA bases 
(Thompson, 1995). Gene mutations may also be inherited (illustrated in figure 1.1.).
                       
 Figure 1.1. Tumour suppressor genes involved in Human cancers (from Harris and Holstein. 1993 
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Orthodox cancer treatments include chemotherapy, radiotherapy, and surgery 
(McWhirter et al., 1996). These treatments have proved to be ineffective cancer 
treatments as a result of its toxicity and cells developing resistance (Curtis et al., 
1992). Kaldor et al., (1990) reported 114 cases of leukemia developing in patients 
treated with concurrent chemoradiotherapy (chemoRT) for ovarian cancer (Kaldor et 
al., 1990). Recent studies in Non-Small-Cell Lung Cancer (NSCLC) demonstrates 
that treatment with chemoRT yields a survival rate of 21% (Le Chevalier et al., 1991) 
while a Phase II study of induction chemotherapy with gemcitabine and vinorelbine 
followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in 
patients with inoperable stage III non-small-cell lung cancer yields a survival rate of 
43,9% (Lee et al., 2005). This multi-drug approach provides a glimmer of hope but 
still leaves much to be desired, as the ideal anti-cancer drug must be selective and 
cytotoxic to cancer cells. Many anti-cancer drugs are derived from natural sources, 
including marine, microbial origin and plants. The FDA approved plant derived drugs 
include Combretastatin A-4 phosphate (Combretum caffrum), Taxol (Taxus 
brevifolia), Velban (Catharanthus roseus) and so on. These chemotherapeutic drugs 
have diverse mechanisms of action. However, their ability to induce programmed cell 
death (PCD) is the unifying event for the mechanisms of chemoprevention (Hadfield 
et al., 2003). 
 
PCD (also referred to as apoptosis) consists of a set of pathways leading to non-
inflammatory cell suicide, as apposed to chaotic, unstructured cell death coined 
necrosis (Kerr et al., 1972). Substantial down-regulation and up-regulation of 
apoptosis leads to cancer and neurodegenerative diseases, respectively.  Thus 
 3 
apoptosis is critical to the development and maintenance of homeostasis in 
multicellular organisms. Apoptosis has been documented to play a crucial role in 
embryogenesis, metamorphosis and morphogenesis (Renehan et al., 2001; Steller, 
1995). Necrotic cell death results from physical injury or disease that causes cell 
membrane damage, with the ensuing cell swelling due to the influx of water and 
sodium ions and consequently inflammation (Kroemer et al., 1998). Distinctively, 
apoptosis displays phenotypic characteristics such as cell shrinkage, chromatin 
condensation, plasma membrane blebbing and DNA fragmentation (Zhao et al., 
2001). The apoptotic bodies resulting from the plasma membrane blebbing are 
phagocytosed thus preventing inflammation (Savill, 1996). These phenotypic 
characteristics result from specific cascading events and are thus proof of the 
existence of distinct pathways for apoptosis.  
 
Apoptotic pathways are being delineated, for the purpose of identifying novel 
apoptosis targets. Inducers or inhibitors of the apoptotic pathways can be used to 
control the substantial up-regulation and down-regulation of apoptosis and 
consequently influence disease states.  
 
 
1.2) Apoptosis 
 
1.2.1) Historical overview of the term apoptosis 
 
Hippocrates of Cos, the father of Western medicine (ca. 460-370 BC) used the term, 
apoptosis for the first time in the textual translation, "the falling off of the bones" 
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describing structural changes (bone erosion) related to tissue and cell death (Degli-
Esposti, 1998). Another notable use of the word apoptosis was in textual translation 
the "dropping of the scabs" denoted by Galen (129-201 AD). This use of the term 
apoptosis relates it to wound healing and inflammation (Hetts, 1998). The term 
programmed cell death was introduced in 1964, proposing that cell death during 
development is not of accidental nature but follows sequential, controlled steps 
leading to defined self-destruction (Lockshin and Williams, 1964). In 1972, the term 
apoptosis was re-introduced into modern scientific writing by Kerr et al and had been 
coined to describe the morphological processes leading to controlled cellular self-
destruction distinct from necrotic cell death (Kerr et al., 1972). 
 
1.2.2) Morphological features of apoptosis 
 
Apoptosis is initiated in normal cells by a variety of stimuli such as, ligation of cell 
surface receptors, a lack of survival signals, developmental death signals, DNA 
damage as a result of defects in DNA repair mechanisms or treatment with cytotoxic 
drugs and/or irradiation. These stimuli leads to the activation of several apoptotic 
pathways with characteristic morphological and biochemical changes (listed in table 
1.1) that are used in the identification of apoptosis (Kerr et al., 1972; Zhao et al., 
2001). An important distinction between necrosis and apoptosis is the fact that cells 
that had undergone apoptosis forms apoptotic vesicles that are phagocytosed by 
macrophages or neighboring cells preventing inflammation (figure 1.2.)  
(Ren and Savill, 1998).
Table1.1. Morphological and biochemical characteristics of apoptosis versus necrosis 
 
 
             Differences 
Apoptosis 
 
Necrosis 
Similarity / variables 
Nuclei Dense condensation 
of chromatin 
Irregular chromatin 
clumping 
Damage occur in both 
Cytoplasmic 
organelles 
Morphologically 
intact 
Disrupted Secondary damage in 
apoptosis 
Cell membrane Cell blebbing Loss of integrity Changes seen in both 
Cell volume Cells shrink Cells swell Occasionally no change 
In tissues Individual cells 
affected 
Groups of cells 
affected 
Superficial epithelial 
cells are apoptotic.  
Tissue response None Inflammation N/A 
Nuclear DNA 
damage 
DNA fragmentation 
(+-200bp), ladder 
visible on gel 
Random DNA 
fragmentation, 
smears on gel 
Takes place in both 
Mitochondrial 
DNA damage 
Occurs late Occurs early N/A 
Cell membrane  Intact Loss of function N/A 
Cell internal 
milieu 
Na+/K+ pump intact 
and ATP required 
Defective Na+/K+ 
pump and no ATP 
N/A 
(Studzinski, 1999) 
 
  
 
 
Figure 1.2. Sketch representation hallmarks of the apoptotic and necrotic cell 
death:  
Apoptosis includes cellular shrinking, chromatin condensation and margination at the 
nuclear periphery which ultimately results in membrane-bound apoptotic bodies / 
vesicles that are phagocytosed without triggering inflammatory responses. The 
necrotic cell swells, disruptes and releases its contents into the surrounding tissue 
causing inflammation (Van Cruchten and Van Den Broeck, 2002). 
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1.2.3) Physiological significance of apoptosis 
 
The development and maintenance of biological systems depends on the refined 
interaction between cells. Throughout development many cells undergo apoptosis 
which contributes to the sculpturing of the organs and tissues (illustrated in figure 
1.3) (Meier et al., 2000). As an example, half of the neurons that are initially created 
during brain formation will die in the later stages of adult brain development 
(Hutchins and Barger, 1998). Also, adult organs maintain homeostasis by constantly 
undergoing physiological cell death which is balanced with proliferation. As an 
example, developing lymphocytes die in the formation of the antigen receptor, 
thereby controlling and maintaining relatively constant numbers of immune cells 
(Rathmell and Thompson, 2002). Holistically, the apoptotic processes are of 
widespread biological significance playing vital roles in development, differentiation, 
homoeostasis, regulation and functioning of the immune system, as well as the 
removal of defective or harmful cells. 
 
Consequently, the abnormal or excessive up-regulation and down-regulation of 
apoptosis is implicated in a variety of pathological conditions. The abnormal or 
excessive down-regulation and/or the termination of apoptosis result in the formation 
of malignant tumors and other diseases such as Autoimmune Lymphoproliferative 
Syndrome (ALPS) (Sneller et al., 1997). Conversely abnormal or excessive up-
regulation of apoptosis leads to other disease states such as Alzheimer’s disease 
(Jellinger, 2001) and Parkinson’s disease (Merad-Boudia et al., 1998). Apoptotic cell 
death is a common discernible occurrence in all kinds of protozoans (Solomon et al., 
1999) and eukaryotes (Ameisen, 2002; Frohlich and Madeo, 2000). Insight into the  
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Figure 1.3. During limb formation separate digits evolve by death of interdigital 
mesenchymal tissue (BabyCenter, 2007). 
 
origin and evolution of apoptosis has been made possible by the identification of 
crucial apoptosis components in the nematode worm, Caenorhabditis elegans 
(Hengartner and Horvitz, 1994). 
 
1.2.4) Molecular mechanisms of apoptosis signaling pathways 
 
1.2.4.1) Various death signals activate common signaling 
 
Apoptosis is a tightly regulated cell death program which requires the interplay of a 
multitude of genes. The components of the apoptotic signaling network are 
genetically encoded in a nucleated cell equipped to be activated by a death-inducing 
stimulus (Ishizaki et al., 1995; Weil et al., 1996). The death inducing stimuli are of 
diverse origin but appear to activate common cell death machinery leading to the 
 7 
characteristic features of apoptotic cell death. In mammalian pathways it is known 
that the B cell leukaemia-2 (Bcl-2) family of proteins plays a central role in the 
decision step of apoptosis whereas the cysteine aspartic-specific proteases (caspase) 
family is essential in the execution of cell death (Alnemri et al., 1996; Chao and 
Korsmeyer, 1998). 
 
The fact that the physiological process of apoptosis has been conserved through 
evolution has contributed immensely to our understanding of apoptosis (Raff et al., 
1993). Genetic analysis of the apoptosis process in C. elegans is a milestone in 
defining key components in mammalian apoptosis pathways (Hengartner and Horvitz, 
1994). It has been established in C. elegans that the cell death defective-9 (ced-9) 
protein binds to the ced-4 protein preventing the onset of apoptosis (Chinnaiyan et al., 
1997). However, external germinal layer-1 (egl-1) negatively regulates ced-9 by 
binding to and directly inhibiting the activity of ced-9, that is, ced-4 is released from 
the ced-9/ced-4 protein complex (Conradt and Horvitz, 1998). The released ced-4 is 
now free to initiate apoptosis by activating ced-3 (Chinnaiyan et al., 1997b). Due to 
the structural and functional similarity of these proteins to their mammalian 
homologues, researchers were able to delineate apoptotic pathways in mammals. The 
ced-9 protein is structurally and functionally similar to the mammalian Bcl-2-like 
survival factors. Likewise, the egl-1 protein is structurally and functionally similar to 
the mammalian Bax-like death factors (illustrated in figure 1.4.) (Hengartner and 
Horvitz, 1994). The ced-4 protein is homologues to the pro-apoptotic protease-
activating factor (Apaf-1) (Yuan and Horvitz, 1992; Zou et al., 1997). The ced-3 
protein is homologues to the mammalian protein interleukin-1 beta converting 
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enzyme (ICE), also known as caspase-1 (Yuan et al., 1993). ICE is an aspartate-
specific cysteine protease and is classified as an effector caspase (Alnemri et al., 
1996).  
 
To date 12 human caspase have been identified, along with the murine caspase 
(caspase-11), the bovine caspase (caspase-13) and a caspase found in most mammals 
(caspase-15) (Eckhart et al., 2005; Koenig et al., 2001; Lamkanfi et al., 2002).  
 
 
1.2.4.2) Key regulatory componenets in apoptosis signaling 
 
1.2.4.2.1) The Caspase family: central initiators and executioners of apoptosis 
 
The caspase family of proteases may be divided into initiator caspases that are 
activated through regulated protein-protein interactions and effector caspases that are 
activated proteolytically by an upstream / initiator caspase (figure 1.4.) (Hengartner, 
2000). 
 
Caspases are synthesized as enzymatically inert zymogens that consist of three 
domains namely, an N-terminal prodomain, a p20 domain and a p10 domain. 
Caspases are usually activated by proteolytic cleavage between these domains. They 
also bind to and associate with upstream regulators due to a protein-protein 
interaction module contained in the prodomain (Chang and Yang, 2000). Caspase-8 
and caspase-10 have a death-effector domain (DED), whereas caspase-9 and caspase-
2 contain caspase activation and recruitment domains (CARD) (Boldin et al., 1996; 
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Li et al., 1997). The death adapter domain mediates intra-family interactions i.e. 
DED/DED or CARD/CARD, but also interact as integration platforms binding to 
different proteins that could modulate their dimerization and hence, caspase activity 
(Chou et al., 1998; Colussi et al., 1998). 
 
 
 
 
 
 
 
 
Figure 1.4. Current nomenclature for human caspases and their corresponding sub-
family groups based on phylogenetic analysis (Lamkanfi et al., 2002; Nicholson and 
Anderson, 2002).  
 
 
1.2.4.2.2) The Bcl-2 family 
 
The Bcl-2 family of proteins is divided into three groups based on structural 
similarity and functional criteria. Group І possesses anti-apoptotic activity, whilst 
Group Џ and Ш promote cell death (illustrated in figure 1.5.). The Bcl-2 family 
controls cell death by forming heterodimers (interaction between pro-apoptotic and 
anti-apoptotic Bcl-2 family members) that mutually neutralize pro-apoptotic and anti-  
HUMAN CASPASES               ORIGINAL NAMES                                      FUNCTION          
      Apoptosis   Other 
Caspase 1    ICE       Inflammation 
Caspase 4      ICE II, TX, ICH-2     Inflammation 
Caspase 5      ICE III, TY     Inflammation 
Caspase 11          ?                          ?           Group 1 
Caspase 12          ?                      ? 
Caspase 13     ERICE      Inflammation 
Caspase 14          ?      Inflammation 
Caspase 3       CPP32, Yama, apopain effector 
Caspase 6      Mch 2   effector              Group 11 
Caspase 7      Mch 2, ICE-LAP3, CMH-1 effector 
Caspase 2      ICH-1   initiator/effector? 
Caspase 8      MACH, FLICE, Mch5 initiator 
Caspase 9      Mch 6, ICE-LAP6    initiator              Group 111 
Caspase 10     Mch 4   initiator/? 
Caspase 15        ?                                               initiator 
 
  
Figure 1.5: Bcl2 family members possess up to four Bcl-2 homology domains (BH1-
4) corresponding to α-helical segments (denoted by coloured boxes). Some members 
also possess a carboxy-terminal hydrophobic trans-membrane (TM) domain (denoted 
by a orange box). The Bcl2 family includes both pro- and anti-apoptotic members. In 
general, anti-apoptotic Bcl2 family members display sequence conservation in all 
four BH domains. Pro-apoptotic members can be assigned to two subsets based on 
sequence conservation: the more fully conserved 'multi-domain' members and a 
divergent subset of 'BH3-domain only' members (Ranger et al., 2001). 
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apoptotic proteins. Thus, the levels of pro-apoptotic and anti-apoptotic Bcl-2 family 
members determine how sensitive the cell is to cell death (Conradt and Horvitz, 1998; 
Ranger et al., 2001). The Bcl-2 family members also protect against cell death 
directly by binding to Apaf-1 and indirectly by regulating the release of pro-apoptotic 
factors from the mitochondrial inter-membrane compartment into the cytosol (Wu et 
al., 1997). 
 
1.2.4.2.3) Regulation of apoptosis by inhibitors of apoptosis proteins (IAP's) 
 
The transcription factor NF-κB up-regulates the expression of pro-survival Bcl-2 
members (Heckman et al., 2002; Karin and Lin, 2002) and transactivates a number of 
other anti-apoptotic genes, such as the inhibitors of apoptosis proteins (IAP's). IAP's 
are a family of anti-apoptotic proteins that contain baculovirus IAP repeat (BIR) 
domains and 70 amino acid motifs. The human IAP homologues; XIAP, c-IAP1 and 
c-IAP2 are thought to directly inhibit caspase-3, -7, and -9 (Salvesen and Duckett, 
2002; Takahashi et al., 1998). The BIR3 domain of XIAP binds directly to the small 
subunit of caspase-9, whereas it is the BIR2 domain that interacts with the active-site 
substrate binding pocket of caspase-3 and -7 (Huang et al., 2001; Srinivasula et al., 
2001). The c-IAP1, c-IAP2, and XIAP also contain a highly conserved RING domain 
at their C-terminal end which possesses E3 ubiquitin ligase activity enabling them to 
catalyze their own ubiquitination, thereby targeting them for degradation by the 
proteasome (Yang et al., 2000), 2000), along with the bound proteins such as 
caspase-3 and -7 (Huang et al., 2000; Suzuki et al., 2001). Crucially, the inhibitory 
activity of the IAP's are counteracted when the negative regulator of IAP's, 
Smac/Diablo, is released from the mitochondrial inter-membrane space during 
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mitochondrial apoptotic events. Smac/Diablo binds to the IAP by displacing the 
caspase bound to it, thus enabling the caspase activation (Du et al., 2000). 
 
 
1.2.4.2.4) Regulation of apoptosis by heat shock proteins (Hsp) 
 
Cells react to chemical and physiological stresses such as heat shock (Hahn and Li, 
1982; Li and Hahn, 1990), chemotherapeutic agents, nutrient withdrawal (Mailhos et 
al., 1993), ultraviolet (UV) irradiation (Simon et al., 1995), polyglutamine repeat 
expansion (Warrick et al., 1999) and TNF (Van Molle et al., 2002), by synthesizing 
heat shock or stress proteins (Hsp). Hsp proteins are broadly categorized according to 
their size (Nollen and Morimoto, 2002). Despite the diversity in the sequence of Hsp 
proteins and the oligomeric assemblies, Hsp proteins have conserved structural 
organization: an N-terminal region that is highly variable in sequence and length, 
followed by a conserved α-crystallin domain and a C-terminal domain (Candido, 
2002; Haslbeck et al., 2004). To date, Hsp proteins that have been implicated in 
apoptosis include Hsp27, Hsp70, Hsp60, αβ-crystallin, and Hsp90. These Hsp 
proteins have displayed the ability to regulate apoptosis as both pro-apoptotic and 
anti-apoptotic inducers.  
 
1.2.4.3) The most extensively researched apoptosis pathways 
 
The most extensively studied apoptosis pathways are the death receptor pathway, the 
mitochondrial pathway and the ER stress signaling pathway. 
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1.2.4.3.1) The death receptor or "extrinsic" apoptosis pathway of type I and type II 
 
Extrinsic apoptosis signaling is mediated by the activation of cell surface receptors 
(death receptors) that transmit apoptotic signals after ligation with specific ligands. 
Death receptors belong to the tumour necrosis factor receptor (TNFR) gene 
superfamily and contain cysteine rich extra cellular sub-domains which allow them to 
recognize their ligands with specificity. Some members of the TNFR family and their 
specific ligands are; CD95/Fas (CD95L/FasL) (Peter and Krammer, 2003), TNFR1 
(TNF) (Nagata, 1997; Smith et al., 1994), DR3 (Apo3L) (Singh et al., 1998), DR4 
(TRAIL-R1) (Merino et al., 2006; Pan et al., 1997), DR5 (TRAIL-R2) (Merino et al., 
2006) and CAR1 (Brojatsch et al., 1996). CD95/Fas signaling is mediated by the 
death receptor inside the cell cytoplasm that contains the conserved sequence termed 
the death domain (DD). Adapter molecules like Fas-associated death domain (FADD) 
or TNFR-associated death domain (TRADD) possess their own DD and DED, 
consequently they are recruited to the DD of the activated death receptor to form the 
death inducing signaling complex (DISC). The conserved DED sequence on the 
adapter molecule forms a homotypic DED/DED interaction by sequestering pro-
caspase-8 to the DISC resulting in high local concentrations of zymogen. Under this 
condition, the low intrinsic protease activity of pro-caspase-8 is sufficient to allow 
various proenzyme molecules to mutually cleave and activate each other (induced 
proximity model) resulting in active caspase-8 (Bodmer et al., 2000). Caspase-8 
activation is regulated by caspase homologue c-FLIP, due to the fact that c-FLIP is 
able to bind to CD95 and TNFR1 preventing the activation of pro-caspase-8 (Chang 
et al., 1999; Chinnaiyan et al., 1995; Salvesen and Dixit, 1999; Srinivasula et al., 
1997). Active caspase-8 then directly activates downstream effector caspase-3 
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resulting in cell death. Cells harboring the capacity to induce cell death directly 
without the assistance of the mitochondrial released proteins, is classified as being 
type I cells (illustrated in figure 1.6.) (Scaffidi et al., 1998). 
  
In type II cells, the caspase signaling cascade does not generate a signal strong 
enough for the execution of cell death. Thus, the signal requires amplification by the 
simultaneous activation of the mitochondria-dependent apoptotic pathway. The 
mitochondria-dependent apoptotic pathway is activated when caspase-8 cleaves Bid 
to form truncated Bid (tBID) that translocates to the mitochondria (Luo et al., 1998). 
The mitochondrial death decision is centered on two processes, the mitochondrial 
outer membrane permeabilization, in which the pro-apoptotic proteins such as tBID 
plays an active roles and inner membrane permeabilization that is promoted by the 
mitochondrial permeability transition pore formed across inner membranes when 
Ca2+ reaches a critical threshold (Belizario et al., 2007). This membrane 
permeabilization leads to the release of release of cytochrome c (Kluck et al., 1997) 
along with the apoptosis inducing factor (AIF) (Susin et al., 1999), Smac/Diablo (Du 
et al., 2000), EndoG (Li et al., 2001) and HtrA2/Omi (Suzuki et al., 2001a). The tBid 
also activates the AIF that is responsible for the externalization of the negatively 
charged phosphatidylserine on the cell membrane (Wang et al., 2002).  
 
The cytochrome c released from the mitochondria disrupts the binding between Bcl-2 
and pro-apoptotic protease activating factor (Apaf-1). Apaf-1/caspase-9 
complexforms active caspase-9 that together with ATP and cytochrome c form the 
apoptosome (Acehan et al., 2002; Adams and Cory, 2002).
  
 
Figure 1.6 There is three major delineated pathways namely; the death receptor 
pathway, the mitochondrial pathway and the ER stress pathway. All three pathways 
lead to the activation of caspase-3 (Gill et al., 2006).
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The activated caspase-9 successively recruits and cleaves pro-caspase-3 to form 
active caspase-3 (Cain et al., 1999). Active caspase-3 mediated cleavage of inhibitor 
caspase-activated deoxyribonuclease IFN (ICAD) resulting in the release and 
activation of the catalytic subunit CAD which is responsible for the fragmentation of 
the DNA into approximately 200bp fragments (Sakahira et al., 1998; Zhao et al., 
2001). Simultaneously, caspase-3 also mediates cleavage of poly (ADP-ribose) 
polymerase (PARP) (Boulares et al., 1999; Kaufmann et al., 1993) and caspase-6 
(Cecconi et al., 1998; Kothakota et al., 1997; Takahashi et al., 1996); thus impeding 
the DNA repair mechanism, and bringing forth lamin protein degradation along with 
the disturbance of the fodrin and gelsolin matrix respectively. As a consequence of 
the above sequence of events, apoptotic cells display characteristic morphology 
changes that are distinct from than seen in necrotic cells. 
 
CD95/Fas induced apoptosis typically involves ligation with adaptor molecule 
FADD. However, an alternative pathway involves the recruitment of an alternative 
adaptor molecule, Daxx that leads to activation of the MAPK apoptosis-signal-
regulated kinase (ASK-1) to induce the activation of MAPK/JNK, leading to 
apoptosis (Chang et al., 1998; Yang et al., 1997). Hsp27 and Hsp70 appear to 
suppress Fas-inducd apoptosis by binding to Daxx and ASK-1, respectively. (Charette 
et al., 2000; Park et al., 2002). Hsp70 suppresses caspase-dependent apoptotic 
signaling by binding to pro-caspase-3 and pro-caspase-7 and preventing their 
activation in U-937 cells. Hsp70 was however, unable to directly bind to activated 
caspase-3 and -7 (Komarova et al., 2004). Hsp27 also binds to pro-caspase-3 to 
prevent its cleavage and activation (Pandey et al., 2000a). Dissimilarly, the small Hsp 
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αβ-crystallin can suppress caspase-8 and cytochrome c mediated activation of 
caspase-3 via a direct interaction with caspase-3 to prevent apoptosis. (Kamradt et al., 
2001). Hsp70 and Hsp27 are also reported to mediate Bid translocation to the 
mitochondria in response to TNF-induced apoptosis (Gabai et al., 2002; Paul et al., 
2002). The interaction between Hsp27 and IKKß is enhanced by TNF-induced, MAP-
kinase-dependent phosphorylation of Hsp27, which leads to an enhanced inhibition of 
IKK activity and consequent suppression of NF- B activity (Park et al., 2003). Gotoh 
et al. have also implicated Hsp70 and its co-chaperones Hsp40 (Hdj-1) or HSDJ (Hdj-
2) in the inhibition of Bax translocation to the mitochondria to prevent nitric-oxide-
induced apoptosis (Gotoh et al., 2004). Hsp70 also inhibits apoptosome formation by 
directly associating with Apaf-1 to prevent activation of pro-caspase-9 (Beere et al., 
2000; Saleh et al., 2000). Hsp90 and Hsp27 are also reported to prevent Apaf-1 
oligomerization by directly associating with Apaf-1 (Pandey et al., 2000b) and 
cytochrome c, respectively (Bruey et al., 2000).  
 
Contrary to the above mentioned Hsp, Hsp60 enhances apoptosis by forming a multi-
protein complex containing pro-caspase-3 and -6 or caspase-8, thus enhancing pro-
caspase-3 activation by caspase-6/-8 in an ATP-dependent manner (Xanthoudakis et 
al., 1999). Hsp60 can also form a complex with Hsp10 and pro-caspase-3 in the 
mitochondria to promote the cytochrome c/ATP-dependent activation of pro-caspase-
3 (Samali et al., 1999). 
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1.2.4.3.2) The mitochondrial or "intrinsic" apoptosis pathway 
 
Above and beyond amplifying and mediating extrinsic apoptotic pathways, the 
mitochondria also play a central role in the integration and propagation of death 
signals originating intrinsically. Intrinsic death signals include; DNA damage, 
oxidative stress, starvation, and the activity of chemotherapeutic drugs (Kaufmann 
and Earnshaw, 2000; Wang, 2001).  
 
Intrinsic death signals activate the TNF ligand to binds to the TNF receptor thereby 
stimulating the accumulation of p53. The p53 protein then initiated the expression of 
the WAF gene producing p21 that binds to the cyclin / kinase complex giving rise to a 
cell cycle restriction site in which an attempt is made to repair the DNA. 
Simultaneously, p53 transcribes the GADD45 gene producing the transcription 
products GADD+PCNA that attempts to repair the DNA damage. If the DNA damage 
is irreparable p53 further initiated the expression of the Bax gene (Vogelstein et al., 
2000). This produces an excess of Bax that gives rise to the Bax/Bax complexes (pro-
apoptotic complex) that displace the Bcl-2/Bax complexes (anti-apoptotic complex) 
because the two complexes compete for the same receptor site on the mitochondrial 
membrane (principle explained above under the Bcl-2 family segment in 1.2.4.3.1) 
(Cheng et al., 1997). The attachment of Bax-Bax complex to the mitochondrial 
membrane brings forth the release of apoptogenic factors (Belizario et al., 2007; 
Vogelstein et al., 2000)  
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1.2.4.3.3) The ER stress signaling pathway 
 
ER death signals include disturbance in calcium homeostasis or an accumulation of 
unfolded/misfolded proteins. These death signals can be triggered by various 
pathophysiological conditions such as Alzheimer's disease (AD), Parkinson's diseases 
and heart disease. However, the cell has protective strategies, commonly referred to 
as the Unfolded Protein Response (UPR), that induce signaling pathways that 
promote the survival of the stressed cell (Chan et al., 2002; Keller et al., 2005). If 
these signaling pathways fail to restore homeostasis then the cell initiates apoptosis 
via the ER stress signaling pathway.  
 
In the ER stress signaling pathway, stress/disturbance of the endoplasmic reticulum 
(ER) homeostasis results in the cleavage of murine pro-caspase-12 that is 
predominantly localized in the ER to form active caspase-12.  The ER-resident active 
caspase-12 directly cleaves other caspases resulting in apoptosis (Shiraishi et al., 
2006). However, the role of caspase-12 in the ER stress pathway is controversial as 
the human genome sequence homologous to the murine genomic sequence for pro-
caspase-12 has been identified at the caspase-1/interleukin-1ß converting enzyme 
(ICE) loci on chromosome 11q22.3 (Fischer et al., 2002), but the gene encoding 
human pro-caspase-12 is interrupted by frame shift and a premature stop codon, and 
has amino acid substitutions in the critical site for caspase activity (Fischer et al., 
2002). This finding is supported by the fact that human caspase-12 has been lost in 
most of the human race except some African descendants (Saleh et al., 2004). Taking 
into account Darwin's concept of the survival of the fittest the question thus arises, 
which caspase in humans has functionally substituted for caspase-12 in mouse.  
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Fascinatingly, the human caspase-4 is located in the same locus and is localized in the 
ER membrane; with only 48 % homology to caspase-12 demonstrates the ability to 
increase ER stress-induced apoptosis and amyloid-ß-induced cell death (Hitomi et al., 
2004). Also, overexpression of Bcl-2 does not affect the cleavage of caspase-4 
suggesting it is primarily activated in ER stress induced apoptosis (Hitomi et al., 
2004). ER stress also induces a disruption of calcium homeostasis as cytosolic 
calcium levels increase. Calcium homeostasis is regulated by the interaction of Bcl-2 
family members with the inositol 1,4,5-triphosphate receptor (InsP3R) ER calcium 
release channel. A significant increase in the calcium level activates calpain. 
Activated calpain cleaves tBid, which translocates to the mitochondria and activates 
the intrinsic pathway (Nakagawa and Yuan, 2000). 
 
 
1.2.5) Genes implicated in cancer 
 
Numerous cancer types have been associated with gene mutations in multiple genes, 
as opposed to a disease such as cystic fibrosis that is characterized by a single gene 
mutation. As an example multiple genes are implicated in non-syndromic 
pheochomocytoma namely, the proto-oncogene RET (associated with multiple 
endocrine neoplasia type 2 [MEN-2]), the tumor-suppressor gene VHL (associated 
with von Hippel-Lindau disease), succinate dehydrogenase subunit D (SDHD) and 
succinate dehydrogenase subunit B (SDHB) (associated with paraganglioma); which 
predispose carriers to pheochromocytomas and glomus tumors (Neumann et al., 
2002). These genes are recognized cancer pre-disposition genes (listed in table 1.2.). 
 
Table1.2. Cancer Pre-disposition genes  
 
 
(Vogelstein and Kinzler, 2004).
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Mutated p53 has been linked to more than 50 % of human cancers (Harris and 
Hollstein, 1993; Vogelstein et al., 2000). Also, virtually all DNA tumour viruses 
encode proteins that inactivate both Rb and p53 (Klein, 2002; zur Hausen, 2001). 
p53, also referred to as the "guardian of the genome", induces cell cycle arrest to 
facilitate the cells integrated DNA repair mechanism. Once the itinerary has been 
exhausted; that is, the DNA damage is irreparable; p53 will induce apoptosis to 
eliminate the cancer cell. This apoptosis pathway is commonly referred to as the 
mitochondrial or intrinsic pathway. This pathway along with other pathways, require 
members of the Bcl-2 gene family and the caspase gene family to secure the 
execution of the apoptotic pathway. Mutated p53 has been implicated in Li-Fraumeni 
syndrome, this cancer is the malignant breast, brain, adrenal etc. tumour (Savage et 
al., 2007).  In colon cancer, germ-line mutations have been identified in the p53 gene 
and the RB gene. These mutations are also accompanied by mutations in the FAP 
gene that leads to the syndrome of familial adenomatous polyposis coli (Cetta et al., 
2000). Under normal apoptotic conditions p53 initiates the expression of the Bax 
gene, a member of the Bcl-2 gene family. The Bax gene has been characterized with 
somatic frameshift mutations of the microsatellite mutator phenotype in colon cancer 
(Rampino et al., 1997). The Bax initiated the release of cytochrome c from the 
mitochondria required for the activation of caspase-9 and -3 respectively. Caspase-3 
mutation has been reported in the MCF-7 breast cancer cell line (Kurokawa et al., 
1999). Similarly, in the extrinsic pathway, Fas gene mutations have been implicated 
in non-small cell lung cancer, caspase-8 gene mutations have been implicated in 
gastric carcinomas and caspase-10 gene mutations have been implicated in non-
Hodgkin lymphomas (Shin et al., 2002; Soung et al., 2005). Researchers are 
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exploiting the biochemical knowledge of the genes associated with cancer, the 
pathways the genes induce and the differences associated with diverse cancer cell 
types, coupled with the action of current anti-cancer drugs, to develop specific non-
toxic drugs. 
 
 
1.3) Plants as sources of anti-cancer drugs 
 
Plants are photosynthetic, eukaryotic, multicellular organisms of the Kingdom 
Plantae that are believed to have evolved from green algae. They range in size and 
complexity from simple mosses to trees. The main plant groups are Phylum 
Bryophyta, Phylum Filicophyta, Phylum Sphenophyta, Phylum Coniferophyta, 
Phylum Cycadophyta and Phylum Angiospermophyta (McWhirter et al., 1996). 
Plants are known to contain many nutritional substances required for the maintenance 
of mammalian cells (McWhirter et al., 1996). Most notably, plants remain the major 
source of carbohydrates making them indispensable to our subsistence (Matthews and 
Van Holde, 1990). Plants perform refined defense mechanisms such as the poisoning 
of the soil with terpenes to inhibit competitors and producing alkaloids which make 
them unpalatable to insects and predators. This fact that plant biology performs tasks 
similar to higher organisms indicates that they may contain secondary metabolites 
compatible to higher organisms (Van Wyk et al., 2000). This fact has already been 
proven as plant secondary metabolites are the biggest source of pharmaceutical drugs 
and they serve as templates for many medicinal derivatives (listed in table 1.3.).  
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Table 1.3 Plant derived pharmaceutical drugs 
Plant Medicinal value 
Opium poppy (Paperver 
somniferum) 
Morphine, a powerful analgesic alkaloid has been 
isolated from the opium poppy. Morphine and its 
derivative codeine is used to treat severe pain and 
headaches respectively (Page, 2005). 
Quinine (Cinchona spp.) Quinine is an alkaloid originally extracted from the 
bark of the quinine tree and is cultivated in South 
America, India, Java and Tropical Africa (Eisenhut 
et al., 2005). 
Amara (Quassia amara) Amara contains bitter terpenoids known as 
quassinoids used as a bitter tonic to improve 
appetite and to treat minor stomach ailments 
(Barbetti et al., 1987). 
Pacific Yew (Taxus spp.) Taxol (Taxus spp.) is a diterpenoid originally 
extracted from the bark of the Pacific yew. Taxol is 
a highly effective drug against breast cancer and 
ovarian cancer (Lanni et al., 1997). 
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The discovery of plant derived drugs epitomizes the importance of using natural 
products and their derivatives to provide new target molecules for drug development 
(Taniguchi et al., 2002; Thatte et al., 2000). Systemic drug discovery and 
development have led to functional chemotherapeutic agents (see section 1.3.2). 
These chemotherapeutic agents have been derived from numerous sources, namely 
viruses, bacteria, plants etc. Plant derived apoptosis inducers or anti-cancer drugs 
include; paclitaxel (Taxol), docetaxel (Taxotere), camptothecin, betulinic acid, 
colchicine, podophyllotoxin and vinblastine, vincristine. These drugs act as DNA 
damaging agents that induce cellular stress by various mean. 
 
 
1.3.1) Cell cycle regulation 
 
Most somatic cells are continually dividing via a highly ordered and regulated process 
called the cell cycle (illustrated in figure 1.7). Cell cycle progression through these 
replication events is regulated at the G1/S checkpoint, the intra-S-phase checkpoint or 
the G2/M checkpoint, if DNA damage activates the DNA repair mechanism. 
 
The DNA repair mechanisms include direct repair base excision repair, nucleotide 
excision repair, double-strand break repair and cross-link repair (Sancar et al., 2004; 
Taniguchi et al., 2002). These DNA repair mechanisms are activated by damage 
sensor proteins such as ATR, ATM, 9-1-1 complex and the Rad17-RFC complex. 
The damage sensor proteins initiate transducers, such as Chk1 and Chk2 Ser/Thr 
kinases and Cdc25 phosphatase that activate p53 and inactivate cyclin dependent 
kinases to inhibit cell cycle progression (illustrated in figure 1.8). 
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Figure 1.7. Cell cycle phases: The cell cycle comprises of four phases namely; G1 
(cell grows), S (DNA replication), G2 (cell prepares to divide) and the M phase (cell 
division) 
 
The G1/S checkpoint prevents cells from entering the S phase in the presence of 
stress thus inhibiting replication. Replication is inhibited as a result of the 
dephosphorylation of CDK2 by the non-phosphorylated Cdc25A proteins, as the 
CDK2 is required for the phosphorylation of Cdc45 that is involved in the initiation 
of replication (Falck et al., 2001; Walter and Newport, 2000). The exact pathway of 
cell cycle arrest depends on the kind of stress induced. DNA double-strand breaks 
leads to the phosphorylation of the damage sensor protein ATM that initiates Chk2 
(Falck et al., 2001). Alternatively, single-stranded breaks result in the activation of  
G1
SM
G2
DNA 
replication
Growth
Growth &
preparation for mitosis 
Mitosis
  
Figure 1.8 DNA repair: mechanisims regulating the cell cycle checkpoints G1/S, 
intra-S-phase and G2/M (Kastan and Bartek, 2004; Taniguchi et al., 2002).
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the damage sensor proteins; Rad17-RFC, 9-1-1 complex and ATR that initiates Chk1 
(Roos-Mattjus et al., 2003; Weiss et al., 2002). Ensuing phosphorylation of Cdc25A 
by Chk1 and Chk2 leads to G1 arrest. ATM and ATR also phosphorylate p53 (Banin 
et al., 1998). p53 initiates expression of the WAF gene, GADD45 gene and the Bax 
gene. The WAF gene produces p21 that binds to the CDK2 complex giving rise to a 
restriction site (Panno et al., 2006). Transcription of the GADD45 gene produces the 
transcription products GADD+PCNA that attempt to repair the DNA damage (Panno 
et al., 2006). If the DNA damage is irreparable p53 further initiates the expression of 
the Bax gene that represents the onset of apoptosis (Taniguchi et al., 2002; Vogelstein 
et al., 2000).  
 
The intra-S-phase checkpoint prevents cells from entering the G2 phase in the 
presence of stress encountered during replication or stress that escaped the G1/S 
checkpoint. The ATM regulates the intra-S-phase checkpoint that is characterized by 
two pathways in response to double-strand breaks induced by radiation. In the first 
pathway, ATM phosphorylates Chk2 on Thr68 through the intermediaries MDC1, 
H2AX and 53BP1 (Burma et al., 2001; Goldberg et al., 2003; Wang et al., 2002). 
Once again, replication is inhibited as a result of the dephosphorylation of CDK2 by 
the non-phosphorylated Cdc25A proteins, as the CDK2 is required for the 
phosphorylation of Cdc45 that is involved in the initiation of replication. In the 
second pathway, ATM initiates phosphorylation of NBS1 of the M/R/N complex, 
SMC1, BRCA1 and FANCD2 (Kitagawa et al., 2004; Taniguchi et al., 2002). 
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The G2/M checkpoint prevents cells from entering the M phase (mitosis) in the 
presence of stress. This checkpoint is very similar to the G1/S checkpoint  as the 
pathway activated depends on the stress induced namely, DNA double-strand breaks 
activates the ATM-Chk2-Cdc25 pathway and DNA lesions such as UV light activate 
the ATR-Chk1-Cdc25 pathway (Adamson et al., 2005; Yamane et al., 2004). At this 
checkpoint, down-regulated Cdc25A, Chk1, Chk2 and WEE1 regulates Cdk2 activity 
and consequently G2 arrest, alongside p53/p21 which is distinct from the G1/M 
checkpoint activities (Matsuda et al., 2006). A second pathway can be initiated at the 
G2/M checkpoint (intra-S-phase checkpoint) namely, ATM initiates phosphorylation 
of NBS1 of the M/R/N complex, SMC1, BRCA1 and FANCD2 (Freie et al., 2004). 
 
 
1.3.2) Current plant-derived anti-cancer drugs 
 
1.3.2.1) Paclitaxel and docetaxel  
 
Paclitaxel (Taxol) and docetaxel (Taxotere) are diterpenoids originally extracted from 
the bark of the Taxus brevifolius (Taxaceae). Paclitaxel binds to the microtubules and 
inhibits their depolymerization (molecular disassembly) into tubulin (Schiff and 
Horwitz, 1980). This inhibiting the cells ability to break down the mitotic spindle 
during mitosis and consequently cells cannot divide into two daughter cells causing 
G2-M arrest (Schiff et al., 1979; Schiff and Horwitz, 1981). Paclitaxel is also 
associated with down-regulation of CDK4 (Yoo et al., 1998) with concomitant G1-S 
arrest. However, the primary effect of paclitaxel is to interfere with the assembly of 
the mitotic spindle, resulting in the failure of chromosomes to segregate (Long and 
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Fairchild, 1994). Paclitaxel is an intravenous drug that is most effective against 
ovarian carcinomas and advanced breast carcinomas. Adverse reactions include major 
breathing problems, edema, abnormally low neutrophil, abnormally low platelet 
counts and anaemia.  
 
Docetaxel also prevents the mitotic spindle from being broken down by stabilizing 
the microtubule bundles, but clinical trials indicate it is two times more effective than 
paclitaxel in this process (Vacca et al., 2002). Docetaxel, is also an intravenous drug, 
that is being tested on carcinomas of the bladder, cervix, lung, and ovaries. Thus far, 
side effects of docetaxel therapy include oedema, abnormally low neutrophil counts, 
and peripheral nervous system disorders.  
 
         
Figure 1.9. The chemical structure of  (A) paclitaxel and (B) docetaxel 
 
 
 
A  B  
 27 
1.3.1.2) Camptothecin and topotecan 
 
Camptothecin is a quinoline-based alkaloid isolated from the bark of the 
Camptotheca acuminata (Nyssaceae). Camptothecin and its close chemical relatives 
aminocamptothecin, CPT-11 [irinotecan], DX-8951f, and topotecan are S–phase-
specific anticancer agents that inhibit the activity of the enzyme DNA topoisomerase-
I (Morris and Geller, 1996). 
 
In 1996, the FDA approved topotecan (manufactured by SmithKline Beecham 
Pharmaceuticals and sold under the trade name Hycamtin) as a treatment for 
advanced ovarian cancers, and irinotecan HCl (manufactured by Pharmacia & Upjohn 
and sold under the trade name Camptosar) as a treatment for metastatic cancer of the 
colon or rectum. Thus far, the major side effects of camptothecin drugs are potentially 
severe diarrhea, nausea, and lowered white blood cell counts.  
 
        
Figure 1.10. The chemical structure of (A) Camptothecin and (B) Topotecan. 
 
A B 
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1.3.1.3) Colchicine 
 
Colchicine, a water-soluble alkaloid, was isolated from the Colchicum autumnale 
(Liliaceae). It suppresses cell division by inhibiting mitosis by binds to the tubulin 
molecule, thereby inhibiting its assembly into microtubules and consequently it 
inhibits the development of spindles as the nuclei are dividing. Cancer cells divide 
more rapidly than normal cells, thus cancer cells are more susceptible to being  
 
 
Figure 1.11. The chemical structure of Colchicine. 
 
poisoned by mitotic inhibitors such as colchicine, paclitaxel, and the Vinca alkaloids 
(Jordan and Wilson, 1998). However, colchicine has proven to have a fairly narrow 
range of effectiveness as a chemotherapy agent, so its only FDA-approved use is to 
treat gout (trade name ColBenemid, an anti-gout drug marketed by Merck & Co.). 
However, it is used in veterinary medicine to treat animal cancers. It is also used as an 
anti-mitotic agent in cancer research involving cell cultures. Thus far, the major side 
effect of colchicine is abnormally low leukocyte levels that can rebound to an 
abnormally high level. 
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1.3.1.4) Podofilox and etoposide 
 
Podofilox was extracted from the Podophyllum peltatum (Berberidaceae). 
Podophyllotoxin (podofilox) and its derivatives, etoposide and teniposide, are all 
cytostatic (antimitotic) glucosides. Etoposide and teniposide both block the cell cycle 
in two specific places i.e. the G1 phase and the S phase and act by causing breaks in 
DNA via an interaction with DNA topoisomerase II. (Clarke et al., 1993). 
Podophyllotoxin (podofilox) is used in creams such as Oclassen's Condylox for the 
treatment of genital warts that are caused by the human papillomavirus (HPV). 
Human papillomavirus (HPV) has been associated with cancers of the genitals 
(squamous cell carcinomas) (Edwards et al., 1988). Etoposide (manufactured by 
Bristol-Myers Squibb and sold under the trade name VePesid) is used mainly to treat 
testicular cancer that has failed to respond to other treatments and is also a first-line 
treatment for small-cell lung cancers, chorionic carcinomas, Kaposi's sarcoma, 
lymphomas and malignant melanomas (Henwood and Brogden, 1990).  
 
                                                                         
Figure 1.12. The chemical structure of (A) Podophyllotoxin and (B) Etoposide. 
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Major side effects include hair loss, nausea, anorexia, diarrhea, and low leukocyte and 
platelet counts. It can also cause genetic damage and may increase a patient's risk of 
developing leukemia. The less popular teniposide have similar side effects to 
etoposide, but is mainly used to treat lymphomas. 
 
1.3.1.5) Vinblastine, vincristine, vindesine and vinorelbine  
 
Vinblastine and vincristine are alkaloids found in Catharanthus roseus (formerly 
classified as Vinca rosea). These vinca alkaloids, vindesine, vinorelbine and the semi-
synthetic derivatives of vinblastine, all work by inhibiting mitosis (cell division) in 
metaphase. These alkaloids bind to tubulin, thus preventing the cell from making the 
spindles it needs to be able to move its chromosomes around as it divides (this is 
similar to the action of colchicine) (Ngan et al., 2001). Although these intravenous 
drugs are very similar in structure and have the same basic action, they have distinctly 
different effects on the body.  
 
Vinblastine (marketed as Velban by Eli Lilly) is mainly useful for treating Hodgkin's 
disease, lymphocytic lymphoma, histiocytic lymphoma, advanced testicular cancer, 
advanced breast cancer, Kaposi's sarcoma, and leukemia (Bleyer et al., 1991; 
Groninger et al., 2005; Stokoe et al., 2001). It also seems to fight cancer by 
interfering with glutamic acid metabolism. Side effects include hair loss, nausea, 
lowered blood cell counts, headache, stomach pain, numbness, constipation and 
mouth sores. Bone marrow damage is the typical dose-limiting factor (Uchida et al., 
1997). Vincristine (marketed as Oncovin by Eli Lilly) is used mainly to treat acute 
leukemia, rhabdomyosarcoma, neuroblastoma, Hodgkin's disease and other 
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lymphomas (Engert et al., 2007; Kang et al., 2007). The typical dose in 1.4 
milligrams per square meter of body surface once a week, and neurotoxicity is the 
dose-limiting factor (it can cause damage to the peripheral nervous system). Side 
effects include those found with vinblastine, plus nervous system problems such as 
sensory impairment; some people may also develop breathing problems or lung 
spasms shortly after the drug is administered (Brockmann et al., 1991; Carpentieri 
and Lockhart, 1978).  
 
                              
Figure 1.13. The chemical structure of (A) Vinblastine and (B) Vincristine 
  
Vindesine (marketed under the names Eldisine and Fildesin) is used mainly to treat 
melanoma and lung cancers (carcinomas) and, together with other drugs, to treat 
uterine cancers (van Luijk et al., 2007). Its toxicity and side effects are similar to 
those of vinblastine. Vinorelbine (marketed as Navelbine by Glaxo Wellcome, Inc.) is 
currently in Phase II clinical trials as a treatment for ovarian cancer (Rothenberg et 
al., 2004). It however seems to have a wider range of antitumor activity than the other 
vinca alkaloids.  In preclinical trials, it showed promise in treating patients with 
A B 
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epithelial ovarian cancers and, in combination with the chemotherapy drug cisplatin, 
in treating patients with non-small-cell lung cancers (Julien et al., 1999). The side 
effects of this drug include diarrhea, nausea, and hair loss; it seems to be less of a 
nerve poison than vindesine. 
 
                                     
Figure 1.14. The chemical structure of (A) Vinorelbine and (B) Vindesine. 
 
Current plant derived anti-cancer drugs primarily target cell division components, 
resultantly; their toxicity is not restricted to cancer cells. Clinical application of these 
drugs has been partially successful as they have been administered in phases and in 
combination with other anti-cancer agents. Phase administered drugs allow the 
patients body to recuperate between doses. This dose dependent administering of 
conventional drugs is however, acutely life threatening to patients. Many 
conventional drugs also induce genetic damage that can itself be carcinogenic. A 
segment of the research community is thus focusing on identifying novel 
chemotherapeutic agents in plants,that do not induce the destructive effects of 
conventional cytotoxic therapeutic agents.  
A B 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1) General chemicals and assay kits 
 
Active Caspase – 3 FITC Mab Apoptosis Kit   BD Biosciences 
Agarose       Promega 
Ampicillin       Roche 
Annexin V- PE Apoptosis Detection Kit 1   Pharmingen 
APOPercentageTM apoptosis assay    Biocolor Ltd 
Bacteriological agar      Merck 
Boric acid       Merck 
Bromophenol blue      Sigma 
Chloroform       BDH 
Crystal Violet       Sigma 
Dichloromethane      BDH 
DAPI (4', 6'-diamidino-2-phenylindole)   Sigma 
DMSO (Dimethyl sulphoxide)    Sigma 
EDTA (Ethylene diamine tetra acetic acid)   Merck 
Ethanol       BDH 
Ethidium Bromide      Promega 
Ethyl acetate       BDH 
Gel Band Purification Kit     Amersham Biosciences 
Glacial acetic acid      BDH 
Glycerol       Merck 
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Hydrochloric acid      BDH 
Illustra GFXTM PCR DNA     Amersham Biosciences  
Methanol       BDH 
N-Butanol       BDH 
Paraformaldehyde      Sigma 
pGEM®-T Easy Vector System    Promega 
Propan-2-ol       BDH 
Proteinase K       Roche 
Silica gel 60 F254      Merck 
Sodium chloride      Merck 
Tris (Tris [hydroxymethyl] aminoethane)   BDH 
Triton X-100 (iso-octylphenoxypolyethoxyethanol)  Roche 
Tryptone       Merck 
Xylene cyanol       BDH 
Yeast extract       Merck 
 
 
2.2) Stock solutions and buffers 
 
10xTBE: 0.9 M Tris, 0.89 M boric acid and 25 mM EDTA, pH 8.3.  
10xTE: 0.1 M Tris-HCl, and 0.01 M EDTA, pH 7.4. 
Chloroform:isoayl alcohol: 24 parts chloroform and 1 part isoamyl alohol 
LB agar: 10g/l Tryptone, 5g/l Yeast extract, 5g/l NaCl and 14g/l Bacteriological agar 
L Broth: 10g/l Tryptone, 5g/l Yeast extract, 5g/l NaCl  
Loading Buffer: 0.25 % Bromophenol blue, 0.25 % Xylene cyanol in 50 % glycerol 
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NR desorb: 1 % Glacial acetic acid, 50 % ethanol and 49 % dH2O  
PI Master Mix: PI (40µg/µl) and RNase A stock (100µg/µl) in PBS. 
RNase A (DNase free): A 20 mg/ml stock solution was prepared in a buffer 
containing 0.1 M sodium acetate and 0.3 mM EDTA(pH 4.8, with acetic acid). This 
stock solution was boiled for 15 min. and cooled in ice water, dispensed into aloquots 
and stored at -20oC. 
TTE: 1xTE, pH7.4, with 0.2 % Triton X-100 
Turks reagent: 0.02 g of crystal violet and 7.2 % glacial acetic acid in dH2O 
2x CTAB buffer (1.4M): 1.4 M NaCl, 100 mM Tris-Cl pH8.0, 20 mM EDTA, 20g/l 
CTAB,  10g/l PVP40. 
 
  
2.3) Tissue culture media and cell lines 
 
Invitrogen supplied tissue culture media: 
Dulbecco’s modified eagle medium (DMEM)       with 4.5g/L glucose, GlutamaxTM  
Ham’s F12 media     with L-glutamine 
RPMI 1640 medium     with L-glutamine 
PBS       with CaCl2 and MgCl2 
100x penicillin streptomycin 
Foetal calf serum (FCS) 
 
Complete Ham’s F12 = Ham’s F12 + 0.2 % penicillin streptomycin + 5 % FCS 
Complete DMEM = DMEM + 0.2 % penicillin streptomycin + 10 % FCS 
Complete RPMI = RPMI + 0.2 % penicillin streptomycin + 10 % FCS 
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Table 2.1. The cell lines used:  
Species Cell lines Medium Serum 
Hamster  CHO 22 Hams F12 5 % FCS 
Human HeLa DMEM 10 % FCS 
Human MCF7 RPMI 1640 10 % FCS 
 
 
2.4) Culturing of cells 
 
 2.4.1) Thawing of cells 
 
The vials of frozen cells were removed from storage at -150oC and immediately 
thawed in a 37oC water bath. The contents of the vials were then transferred into a 15 
ml tube containing 5 ml Hams F12 media. The 15 ml tube was centrifuge for 2min. at 
300 xg. The supernatant was discarded whilst the pellet was resuspended in 5 ml 
Hams F12 media and transferred to a 25cm2 tissue culture flask for incubation. All the 
cell lines used were adherent and were incubated at 37oC in an atmosphere of 5 % 
CO2. 
 
 
2.4.2) Trypsinization of cells 
 
The cells were trypsinized once cells reached confluency. The Hams F12 media in the 
flask was discarded. Cells were washed with trypsin, then allowed to trypsinize with 
3 ml of 0.0625 % Trypsin at 37oC. Cells completely trypsinized in 3 min. 12 ml of 
Hams F12 media were then added to stop trypsinization. The cells were split into 
three 25cm2 tissue culture flasks for incubation in Hams F12 media. 
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2.4.3) Freezing of cells 
 
To store cells, cells were trypsinized and centrifuged after which the cell pellet was 
re-dissolved in a 10 % DMSO and 90 % Hams F12 media mixture. The suspensions 
were aliquoted into 2 ml cryo-vials, then stored at -150oC. 
 
 
2.4.4) Seeding of cells  
 
Once cells were thawed and incubated in a 25cm2 tissue culture flask, cells were 
incubated at 37oC for 48 h to 72 h to grow to confluency, Cells are then trypsinized, 
centrifuged to remove supernatant and re-suspended in 5 ml of Hams F12 media. 
Cells were counted using a Hausser Scientific Fuchs Rosenthal Ultra Plane 
Hemocytometer and seeded at a concentration of 2.5x104 cells per well. When 6, 24 
or 96 well plates were used 2 ml, 500 ul or 100 ul of cells were seeded respectively. 
Cells were incubated overnight at 37oC and were ready for testing. 
 
 
2.5) Tests authenticating the induction of apoptosis 
 
2.5.1) Cytotoxicity assay 
 
CHO (Chinese Hamster Ovary) cells were seeded in 96 well tissue culture plates and 
tested for 24 h with varying concentrations in triplicate. The supernatant was removed 
from the wells, cells were washed with 2 ml PBS and 100 µl of neutral red (NR) 
solution (100 µg/ ml, in serum free media) was added to each well. The plates were 
incubated for 2 h at 37°C. Wells were washed rapidly with 100 ul, 1 % 
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paraformaldehyde. The NR dye was extracted from the cells by adding 100 ul of NR 
desorb to each well, plates were incubated for 15 min., then placed on a shaker for an 
additional 30 min. before determining the optical density at 540 nm (OD540) on a 
multiwell spectrophotometer.  Cytotoxicity is calculated as follows: 
 
 
 
 
 
 
2.5.2) APOPercentageTM assay 
 
The APOPercentageTM dye was prepared by adding 15.9 ml F12 (Hams) media to 0.1 
ml APOPercentageTM dye. Cells were seeded in 24 well tissue culture plates and 
tested for 24 h with varying concentrations of plant extract in triplicate. After the cells 
were treated with the plant extract, the extracts were tranfered to 15 ml tubes. Cells 
were washed with 1 ml PBS and trypsinized with 300 ul trypsin that were both added 
to the removed extract. Cells were centrifuged at 500 xg for 5 min. Cells were re-
suspended in 200 ul of the prepared APOPercentageTM dye, followed by incubation 
for 30 min. at 37°C. The cells were washed with 2 ml PBS to remove excess dye. The 
cells were analyzed by flow cytometry. 
 
 
2.5.3) Annexin V- PE Apoptosis Detection assay 
 
The assay was performed using the Annexin V-PE Apoptosis Detection Kit (BD 
Biosciences). The manufacturers' protocol was followed. CHO cells were seeded in 
% cytotoxicity = Abs of negative control – Abs of treated cellsAbs of negative control 
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24 well tissue culture plates and cells were induced with extract for 6 h. After the 
cells were treated with the plant extract, the cells were washed with cold PBS. The 
cells were then trypsinized and re-suspended in 500 µl 1 x binding buffer. To each 
suspension 5 µl of Annexin V-PE and 5 µl of 7-AAD was added. Suspensions were 
then gently vortexed and incubated for 15 min. at room temperature in the dark. The 
cells were analyzed by flow cytometry. 
 
 
 
2.5.4) Active Caspase 3 - PE Mab Apoptosis 
 
The assay was performed using the Active caspase 3-PE Apoptosis Kit (BD 
Biosciences). The manufacturers' protocol was followed. CHO cells were seeded in 
24 well tissue culture plates and cells were induced with extract for 6 h. After the 
cells were treated with the plant extract, wells were washed with PBS; cells were 
trypsinized and re-suspended in 0.5 ml Cytofix/Cytoperm, then incubated on ice for 
20 min. The cells were centrifuged at 500 xg for 5 min. The cell pellets were washed 
twice with 0.5 ml Perm/Wash buffer followed by centrifugation. Each sample was re-
suspended in 100 µl of Perm/Wash buffer and 20 µl of antibody. The samples were 
then incubated for 30 min. at room temperature. The samples were washed with 1 ml 
Perm/Wash buffer, and re-suspended in 0.5 ml Perm/Wash buffer. The cells were 
analyzed by flow cytometry. 
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2.5.5) APO-DIRECT™ Kit 
 
The assay was performed using the APO-DIRECTTM Kit (BD Biosciences). The 
manufacturers' protocol was followed. CHO cells were seeded in 6 well tissue culture 
plates and cells were induced with 5 mg/ml plant extract for 48 h. After treatment 
with the plant extract, cells were trypsinized and re-suspended in 5 ml of 1 % (w/v) 
paraformaldehyde in PBS and placed on ice for 15 min. The cells were centrifuged at 
500 xg for 5 min. and the supernatant was discarded. Cells were washed in 5 ml of 
PBS followed by centrifugation at 500 xg for 5 min. The wash step was repeated. The 
cells were re-suspended in 0.5 ml of PBS, to which 5 ml. of ice-cold 70 % (v/v) 
ethanol was added. Cells were stored at –20oC for 48 h. The cells were centrifuged at 
500 xg for 5 min. and the supernatant was discarded. Each cell pellet was re-
suspended in 1 ml of wash buffer. Samples were centrifuged as before and the 
supernatant was removed by aspiration.  The wash step was repeated. The cells were 
re-suspended in 50 ml of the staining solution and incubated for 60 min at 37oC. 1 ml 
of Rinse Buffer was added to each tube and centrifuged as before. The supernatant 
was removed by aspiration. The cell rinsing step was repeated. The cells were 
resuspended in 0.5 ml of the Propidium Iodide/RNase A solution and incubation in 
the dark for 30 min. at room temperature. The cells were analyzed in Propidium 
Iodide/RNase solution by flow cytometry. 
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Table 2.2 APO-DIRECTTM kit staining solution 
Staining Solution 1 Assay (µl) 4 Assay (µl) 
TdT reaction 10 40 
TdT enzyme 0.75 3 
Fluorescein-dUTP 8 32 
dH2O 32 128 
Total volume 50.75 203 
 
 
2.6) Phylogenetic studies  
 
2.6.1) 2x CTAB DNA extraction 
 
Liquid nitrogen was added to 50 mg of leaf material to facilitate the grinding of the 
leaf material to a fine powder. 1 ml of 2 x CTAB buffer preheated to 62ºC was mixed 
with the fine powder to obtain a consistent slurry. This mixture was incubated at 62ºC 
for 30 min., then allowed to cool for 10 min. at room temperatue before 10 µl of 10 
mg/ml Proteinase K was added. The samples were incubated at 37ºC for 30 min. 
Equal volumes of CIA was added to each sample followed by gentle mixing. The 
sample was centrifuged at 10 000 xg for 10 min. The top aqueous layer was collected 
and 2/3 v/v ice-cold isopropanol was added to the collected aqueous layer. The 
samples were mixed by inversion, then samples were incubated at 4ºC for 20 min. 
The samples were centrifuged at 10 000 xg for 10 min. then the supernatant was 
discarded. The cells were washed twice with 500 µl ice-cold 70 % EtOH. The cells 
were air-dried, re-suspended in 100 – 200 µl TE buffer containing RNase (0.0625 
mg/ml final concentration) then incubated at 37ºC for 30 min. The DNA was re-
precipitataed with 0.5 v/v 7.5M NH4Ac and 2.5 v/v cold Abs EtOH was added. The 
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sample was incubated for 30 min. at -20ºC. The samples were centrifuged at 10 000 
xg for 10 min. The DNA was air-dried and re-suspended in TE buffer. 
 
2.6.2) Polymerase Chain Reaction (PCR) 
 
PCR reactions were performed in 10x reaction buffer. The enzyme Taq polymerase 
was used at 0.2 units per reaction. The primers were present at 1 pmol, MgCl2 
concentration was 1.5 mM and 10 ng of DNA template was used in each reaction. 
Table 2.3 describes the experimental set up of each PCR reaction. 
 
Table 2.3. Experimental set up of the PCR reactions 
 Final 
Concentrations 
10x Reaction buffer 1x 
dNTP's 100µM 
Forward primer 1µM 
Reverse primer 1µM 
dH2O  
Taq 0.2u 
DNA template ~10ng 
Total reaction volume  
 
The PCR cycling conditions were as follows: 95°C for 10 min.; 95°C for 30 sec.;  
56°C for 30 sec.; 72°C for 30 sec.; repeated for 30 cycles; followed by 72°C for 7 
min. The successes of the PCR process were assessed by agarose gel electrophoresis.  
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2.6.3) Agarose gel electrophoresis of DNA 
 
To 2 µl of the DNA sample prepared (as per method set out in 2.5.5.1), 2 µl of 
loading buffer was added. Samples were loaded alongside the molecular weight 
marker on a 1.5 % agarose gel containing 1 µl EtBr per 100 µl 1 x TBE buffer. The 
samples were electrophoresed at 10 V/cm in 1 x TBE buffer. DNA was visualized 
with a UVP transilluminator. 
 
 
2.6.4) Purification of DNA fragments   
 
The PCR product was visualized under a UV lamp and cut out of the agarose gel with 
a sterile single-use carbon steel surgical blade. The PCR product or DNA fragments 
were macerated followed by purification using the Illustra GFXTM PCR DNA and Gel 
Band Purification Kit (according to manufacturers' instruction). 
 
 
2.6.5) Cloning PCR fragments into pGEM®-T Easy   
 
PCR fragments were cloned using the pGEM®-T Easy Vector System (Promega). 
Table 2.4 describes how the ligation reactions were set up.  
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Table 2.4. Experimental set up of the ligation reaction 
 Final 
concentrations 
2x  Rapid ligation buffer 1x 
pGEM®-T Easy (1ng/ µl) 0.1ng 
PCR product 0.05ng 
Control insert 0.05ng 
dH2O  
T4 DNA ligase (1 unit/ µl) 1u 
Total reaction volume  
 
The ligation reactions were briefly mixed and incubated overnight at 4°C. For the 
transformation process, 100 µl competent E. coli cells were added to the ligation 
reactions. The mixtures were incubated on ice for 20 min. The cells were then heat 
shocked at 42°C for 30 sec. followed by incubation on ice for 5 min. Each tube was 
filled up to 1 ml with pre-warmed L-Broth and incubated at 37°C with shaking. After 
30 min., 100 µl of the transformed culture was plated an LA agar plates containing 
100 µg/ ml ampicillin and incubated at 37°C overnight. 
   
 
2.6.6) Colony PCR and sequence analysis  
 
Following the transformation process, colonies to be screened were removed from the 
plate and re-suspended in 100 µl deionised water. E. coli colonies were screened for 
the presence of the insert by colony PCR. Table 2.5 describes the colony PCR 
reactions.  
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Table 2.5. Experimental set up of the colony PCR 
 
Final 
concentrations 
10x Reaction buffer 1x 
dNTP's 100µM 
M13 Forward primer 1µM 
M13 Reverse primer 1µM 
dH2O  
Taq 0.2u 
Colony cell suspension  
Bacterial cell suspension  
Total reaction volume  
 
The PCR cycling conditions were as follows: 95°C for 10 min.; 95°C for 30 sec.; 
95°C for 30 sec.; 58°C for 30 sec.; 72°C for 30 sec.; repeated for 35 cycles; followed 
by 72°C for 7 min. The successes of the colony PCR process were assessed by 
agarose gel electrophoresis.  
 
.The colony PCR product were spread on L-agar plates and grown at 37°C. Positive 
clones were sent for sequencing at Inqaba Biotechnical Industries (Pty) Ltd, South 
Africa. Glycerol stocks were prepared of the positive clones, by dilution of the culture 
with an equal volume of 80% sterile glycerole. These were then stored at -80°C 
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2.7) Methods of fractionation 
 
 
2.7.1) Aqueous extraction 
 
The plant material was cut to increase the surface area, and then dried in an oven at 
40oC overnight. The dried plant material was blended to a powder and 10g was 
weighed out and mixed with 500 ml distilled water. This mixture was then stirred for 
16 h. The supernatant containing the extracted secondary metabolites was then 
removed and the extraction step was repeated twice on the same plant material. The 
extracted mixture was then filtered, frozen at -80oC and then freeze dried. The dried 
extracted secondary metabolites were weighed and re-dissolved in distilled water to 
produce a 40 mg/ml stock solution that was stored at -20˚C.  
 
 
2.7.2) Organic solvent extraction 
 
The active aqueous extracts were individually fractionated by organic solvent 
extraction.  The aqueous extract was mixed vigorously with acetone in a 1:4 ratio. 
The solvents were then placed in a separation funnel  and allowed to phase separate. 
The acetone was removed; another 80 ml of acetone was added to the 20 ml aqueous 
extract in the separation funnel. The extraction step was repeated in triplicate on the 
same aqueous extract. The same extraction procedure was used for other solvents 
with increasing polarity (except that a 1:1 ratio was used). The other solvent used was 
n-butanol 3.9, ethyl acetate 4.3, chloroform 4.4, petroleum ether 5 (polarity of 
solvents represented by bold numeric following the solvent name). The solvents were 
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then evaporated using a rotary evaporator and the concentrations of the extracts were 
established. The extracts were re-dissolved in ethyl acetate, as it had been determined 
that 1 % ethyl acetate is not toxic to the cells. Thus, for testing purposes 0.5 % ethyl 
acetate concentrations were used. 
 
The stock solution was diluted with Hams F12 media to produce different 
concentrations of the extract for testing purposes. These different dilutions of plant 
extracts were filtered (through a 0.22 micro-pore cameo filter) before screening for 
induction of apoptosis. 
 
2.7.3) Thin Layer Chromatography (TLC) 
 
 
2.7.3.1) Determining the solvent system need to separate extract by TLC 
 
Before performing TLC or LCC, the solvent system needed to separate the 
compounds was determined. TLC aluminium sheets (20 x 20 cm; silica gel 60 F254) 
were cut into 10 cm x 1.5 cm rectangles. A light pencil line was drawn 1 cm from the 
bottom and top edge of the chromatographic plate. The sample was spotted on this 
line (<0.5 mm in diameter) and placed in a developing chamber. The solvent was 
allowed to migrate up the plate via capillary action until the pencil line drawn across 
the top edge was reached. The plates were then examined under ultraviolet (UV) 
light. A solvent that results in strong mobility of the extract and one in which the 
extract remains stationery are combined in different ratios. The ratio that best 
separates the extract into different layers is utilized as the solvent system for TLC 
and/or LCC.  
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2.7.3.2) Concentrated compound fractionation by TLC 
 
A TLC glass plate (20 x 20 cm; silica gel 60 F254) was used for the fractionation of 
compounds. A light pencil line was drawn 1cm from the bottom and top edge of the 
chromatographic plate. A capillary was used to streak the extract across the bottom 
edge as thinly as possible. A developing chamber was filled 0.5 cm with the solvent 
system established above. The solvent migrated up the plate via capillary action until 
it reaches the pencil line drawn across the top edge. The TLC plate was removed from 
the developing chamber, and allowed to air-dry. The plates were examined under 
ultraviolet (UV) light and the layers were outlined with a pencil. The Rf values for 
each layer were calculated (illustrated in figure 2.1), as unknowns can be identified 
using Rf values. Each layer of silica/ extract was scrapped off the TLC glass 
separately. 
 
 
Rf   =   the distance of the starting point to the top of the spot 
           the distance of the starting point to the solvent front 
 
Figure 2.1. Illustration of how the Rf was calculated. The Rf equals the distance of 
the starting point to the top of the spot divided by the distance of the starting point to 
the solvent front. 
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To separate the silica from the extract, a cotton stopper was firmly placed in a 
column, followed by the silica/extract, and then 100 % of the solvent in the solvent 
system was poured into the column. The extract eluted in the solvent that is captured 
in a beaker placed beneath the tap of the column. Fractions were then dried by rotary 
evaporation and re-dissolved in ethyl acetate and tested for apoptosis activity. 
 
 
2.7.4) Liquid Column Chromatography (LCC) 
 
A chromatography column was set up and approximately 75% of the column was 
filled with silica. A 1-2 cm layer of silica was mixed with extract then the mixture 
was dried by rotary evaporation to bind the extract to the silica. The layer of extract 
bound silica was placed on the clean silica in the column. A cotton plug was placed 
on the silica to prevent the extract from re-dissolving into the solvent system. A small 
quantity of solvent system was added slowly to the column to settle the cotton plug. 
The column was filled with solvent and the solvent level was maintained. The eluting 
solvent was captured by a fraction collector. The fractions collected were spotted on 
TLC plates to establish distinction in fractions collected. Fractions were then dried by 
rotary evaporation, re-dissolved in ethyl acetate and tested for apoptosis activity. 
 
 
2.7.5) Reverse-Phase High Performance Liquid Chromatography (RP-HPLC) 
 
Samples were monitored and fractionated using the Beckman HPLC system in 
combination with the chromatography station with Windows, ClarityTM DataApex 
and collected using the FOXY JR 202F20077 fraction collector. The Beckman HPLC 
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system consisted of an autosampler 501, organizer 340, 2 x solvent delivery system 
module 110 and the Knauer variable wavelength monitor. 
 
The chromatographic conditions for the analytical C-18 250 x 4.6mm Luna 5u 
(Phenomex): Mobile phase solvent A consisted of 1 % acetic acid in water (v/v) 
mobile phase solvent B consisted of 100 % methanol. The gradient was premeditated 
as followes: the column was equilibrated with 100 % solvent A and 0 % solvent B for 
5 min. then solvent A was decreased to 60 % and solvent B was increased to 40 % for 
10 min. Solvent A was then decreased to 40 % and solvent B was increased to 60 % 
in 2 min. This solvent system remained constant for 10 min. Solvent A was then 
further decreased to 20 % and solvent B was increased to 80 % in 2 min. This solvent 
system remained constant for 10min. Solvent A was decreased to 0 % and solvent B 
was increased to 100 % in 2 min. This solvent system remained constant for 10 min. 
Solvent A was decreased to 100 % and solvent B was increased to 0 % in 2 min. and 
remained constant for 5 min. to re-equilibrate the column in preparation for 
subsequent fractionations. 
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CHAPTER 3: SCREENING INDIGENOUS SOUTH 
AFRICAN PLANTS FOR PRO-APOPTOTIC ACTIVITY  
 
3.1) Introduction 
 
The use of traditional medicine has a long history and is still the major source of 
medicine in developing countries. Approximately 70 % of the South African 
population consults traditional healers, perpetuating the need for scientific appraisal 
of traditional medicine as a means to establish its efficiency and safety (Puckree et 
al., 2002). Also, pharmacological and phytochemical insights into several plants have 
led either to the discovery of novel chemicals and therefore novel drugs, or to novel 
chemical structures that can serve as lead compounds/templates for the design of new 
drugs (section 1.3.1). Natural product research has thus been developed specifically 
for the isolation of secondary metabolites with a particular biological activity.  
 
Plants contain two classes of compounds namely; primary metabolites that are 
required for the livelihood of the plant i.e. the plants machinery, and the secondary 
metabolites that are not a necessity for the plants survival. Some secondary 
metabolites protect plants against fungi, bacteria, insects, and viruses. Extracted 
secondary metabolites have been used as food flavourants, colour dyes, poisons, 
perfumes, industrial products (e.g. oil) and prescription drugs, however the functions 
of majority of the secondary metabolites are not known (Wink, 1999). Plant derived 
secondary metabolites and their derivatives have also been a major source of anti-
cancer drugs. 
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The identification and purification of bioactive secondary metabolites from plant 
extracts can be a tedious and expensive operation. In an attempt to cut down on the 
cost of drug discovery and to increase the probability of identifying useful secondary 
metabolites, research methodology allows the screening of multiple natural products 
for prospective drug development. One approach is to screen plants with well-known 
ethno-medicinal value, although it has been established that the ethno-medicinal data 
obtained for a plant extract is not necessarily a reliable source (Cragg et al., 1994). 
However, there also seem to be a greater possibility of finding biological activity 
among plants with ethno-medicinal value rather than from plants randomly selected 
(Chapuis et al., 1988; Cordell et al., 1991). The second approach is to use the rapid, 
inexpensive and highly automated bioassay screening methods. With respect to anti-
cancer drug screening it is believed that cytotoxicity and cell viability assays provide 
important preliminary data to help select plant extracts with potential anti-cancer 
properties for future work (Cardellina et al., 1993). This strategy is based on the fact 
that these assays measure cell death or inhibition of cell growth and that a potential 
anti-cancer drug will either inhibit cancer growth or kill cancerous cells. However, 
most of these assays do not discriminate between toxic cell death and cell death 
induced by apoptosis. Colorimetric bio-assays, such as the APOPercentageTM assay, 
specifically detect and quantify apoptosis, making them better high-throughput, 
inexpensive accurate preliminary screen of pro-apoptotic activity. However, accurate 
quantification of the pro-apoptotic activity is lacking. This dilemma has been solved 
by analyzing APOPercentageTM assay results by FACScan.  The conventional 
APOPercentageTM assay requires 100 µl of 1/20 dilution of APOPercentageTM dye 
per reaction whereas, APOPercentageTM assay/FACScan only require 100 µl of 1/160 
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dilution of APOPercentageTM dye. The APOPercentageTM assay/FACScan results are 
thus more laborious to obtain but preferable as they are quantitative (Johnson et al., 
2003). 
 
The objective of this section was to do comparative screening of poisonous native 
South African plants with and without ethno-medicinal value (listed in table 3.1.). 
Thus, the present enquiry reports on the cytotoxicity (using the neutral red 
colorimetric assay) and apoptosis activity (using the APOPercentageTM assay, 
Biocolor Ltd) of the aqueous extracts of nine native South African plants on three cell 
lines namely MCF7 (human breast adenocarcinoma), HeLa (human cervical 
carcinoma) and the 'normal' animal cell line, CHO (Chinese Hamster Ovaries). All 
experiments were repeated thrice to ensure that the results obtained were accurate and 
reproducible. The cytotoxic and apoptotic activity was used to identify the plant 
extract with the most significant anti-cancer activity. This plant pro-apoptotic activity 
was demonstrated with more specific markers of apoptosis namely the externalization 
of phosphatidylserine, caspase-3 activation and DNA fragmentation.  
 
The nine plants screened were; the poisonous Cotyledon orbiculata, Oxalis pes 
caprae, Echium plantagineum, Cissampelos capensis, Euphorbia mauritanica, 
Haemanthus pubescens, Cynanchum africanum and the non-poisonous Lessertia 
frutescens and Elytropappus rhinocerotis (see the pictorial representation in figure 
3.1.). Some of these plants are used as traditional remedies to treat cancer. Except for 
                    
Plant species (family) Common name Distribution Traditional medicinal uses Some reported pharmacological activies References
Cotyledon orbiculata (Crassulaceae) pigs ears Southern Africa boils, inflammation, earache, syphilis, four bufadienolides; orbicusides A, B, C 
 ulcers and tyledoside C causes ‘krimpsiekte’ in stock Steyn et al. 1986
Oxalis pes caprae (Oxalidaceae) yellow sorrel Western Cape arthritis, asthma, boils, burns, cancer, oxalates are poisonous to humans and animals Bruneton. 1999
tuberculosis, tumors
Echium plantagineum (Boraginaceae) Western Cape Province n/a heliosupine, echimidine, echiumie etc.these
toxins accumulatively cause liver damage in animal Van Wyk et al. 2000
Cissampelos capensis (Menispermaceae) dawidjies Western parts of South Africa diabetes, tuberculosis, urinary stones, n/a
stomach and skin cancer
Euphobia mauritanica melkbos Southern Africa: western n/a cause fatal nervous disorder in sheep characterized 
parts and dry interior by muscle tremers, bloat, diarrhoea and fever Kellerman et al. 1988
Haemanthus coccineus April's fool ulcers, anthrax, edema, diuretic, asthma n/a
Cynanchum africanum (Asclepiadaceae) bobbejaantou Cape Peninsula: Namaqualand to n/a cause cattle and sheep poisoning called cynanchosis Kellerman et al. 1988
Port Elizabeth
Lessertia frutescens (Fabaceae) cancer bush Southern Africa: Western Cape, chickenpox, diabetes, hemorrhoids, L-canavanine has documented anti-cancer activity Swaffer et al. 1995
Estern Cape, Namibia, Karoo. rheumatism, cancer
Elytropappus rhinocerotis (Asteraceae) renosterbos Western Cape and Eastern ‘flu, indigestion, lack of appetite, ulcers rhinocerotinoic acid, a diterpene with anti-
Cape and stomach cancer. inflammatory properties Dekker et al. 1988
Table3.1. Plants screened to treat conditions consistent with cancer symptomatology
    
A) C. orbiculata
E) E. plantagineum
B) O. pes caprae
G) H. pubscens
D) L. frutescens
H) E. rhinocerotis
F) C. capensis
C) C. africanum
I) E. mauritanica
Figure 3.1. Pictorial representation of the nine indigenous South African plant screened for apoptosis activity. 
A represents Cotyledon orbiculata. B represents Oxalis pes caprae. C represents Cynanchum africanum. D 
represents cytotoxicity and apoptosis activity induced by Lessertia frutescens. E represents Echium
plantagineum. F represents Cissampelos capensis. G represents Haemanthus pubescens H represents 
Elytropappus rhinocerotis. I represent Euphorbia mauritanica.
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L. frutescens none of these plants have reported anti-cancer activity. An anti-cancer 
compound in L. frutescens has been identified as L-canavanine (Crooks and 
Rosenthal, 1994; Swaffar et al., 1994). L. frutescens displays significant pro-
apoptotic activity on numerous cell lines including; CHO, Jurkat (human T cell 
leukemia) and MCF7 (Chinkwo, 2005; Tai et al., 2004). Cotyledon orbiculata, Oxalis 
pes caprae, Echium plantagineum, Euphorbia mauritanica and Cynanchum 
africanum has been documented to be poisonous to animals (Table 3.1.). 
 
 
3.2) Aqueous extraction of plant secondary metabolites 
 
Traditional remedies necessitate the extraction of plant secondary metabolites by 
boiling in water. This extraction method allows for the indiscriminate extraction of 
the secondary metabolites, a method perfectly apt for the screening of an unknown 
secondary metabolite.  Efficiency of the aqueous extraction process was ensured by 
the effective drying, blending and grinding of the plant material, as this process 
assists with the penetration of the solvent to the plant cellular structure to dissolve the 
secondary metabolites i.e. it increased the yield of extraction by increasing the surface 
area (Cannell, 1998). 
 
A 40 mg/ml stock solution of aqueous extracted plant extract was prepared using the 
method described in section 2.6.1 and was stored at -20˚C. The aqueous extraction 
produced yields between 4 % and 10 % of dry plant product compared to the mass of 
the dry plant product used as the starting material in the extraction (Table 3.2.). 
Table 3.2 Yields associated with the aqueous extraction of the dry plant material
7.3lf,st10KirstenboschSeptemberE. rhinocerotis
7.6lf,st10BlaauwbergSeptemberE. rhinocerotis
7.1lf,st10HelderbergSeptemberE. rhinocerotis
7.3lf,st10TygerbergSeptemberE. rhinocerotis
8.2lf,st10TulbaghJulyE. rhinocerotis
5.4lf,st10Cape FlatsJulyC. africanum
6.0lf,st10WellingtonJulyL. frutescens
5.7lf10Cape FlatsJulyH. coccineus
6.1lf,st10Cape FlatsJulyE. mauritanica
4.2lf,st10Cape FlatsJulyC. capensis
6.4lf,st10Cape FlatsMayE. plantagineum
4.2lf,st10Cape FlatsMayO. pes caprae
5.8lf10Cape FlatsMayC. orbiculata
Yield
(%)
Plant 
part
Dry weight 
(g) 
Area of 
collection
Time of 
collection
Plant species
*lf - leaf; st - stem  
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3.3) Analysis of the cytotoxic and pro-apoptotic effects of plant extracts 
 
3.3.1) Screening cytotoxic effects of plant aqueous extracts using the neutral red 
(NR) assay 
 
The neutral red (NR) cytotoxicity assay is a cell viability assay, based on the ability 
of viable cells to incorporate and bind the NR dye. NR is a weak cationic dye that 
penetrates cell membranes by non-ionic diffusion. It accumulates intracellular at the 
anionic sites in the lysosomal matrix. Alterations in the cell membrane or the 
sensitive lysosomal membrane leads to lysosomal fragility (Borenfreund and Puerner, 
1985). As a consequence only cells that are intact / viable will bind NR dye i.e. the 
viable cells with an intact lysosomal membrane will be dye stained with the dye while 
the dead cells with lysosomal membrane damage will not be labelled. They dye 
trapped within live cells can be releasd, quantified and expressed as a function of cell 
death.  
 
Cells were plated in 96 well tissue culture plates as described in section 2.5.1.  The 
cells were treated with aqueous extract of all plants used for 24 h. The concentrations 
ranged between 0.625 mg/ml and 5 mg/ml. Cytotoxicity effect was measured by the 
colorimetric Neutral red assay. The cytotoxicity induced by individual plant extracts 
are presented on Figure 3.2, 3.3 and 3.4 (in blue) that represent the MCF7, Hela, and 
CHO cell lines respectively.  
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The aqueous extract of C. orbiculata is the only extract tested that displays induction 
of noteworthy cell death or high levels of cytotoxicity in the breast cancer cell line 
(MCF7) presented in figure 3.2, whereas C. capensis, E. mauritanica, H. pubescens, 
C. africanum and C. orbiculata display signs of considerable cell death or high levels 
of cytotoxicity in the cervical cancer cell line (HeLa) presented in figure 3.3. 
However, cytotoxicity is negligible (below 40 %) in the non-cancerous cell line 
(CHO) for all plant extracts tested. These results indicate that cytotoxicity induced 
were specific to the cells lines tested as cytotoxicity is not constantly induced in all 
the cell lines. The question now arises, is the cell death a consequence of pro-
apoptotic activity or necrosis? 
 
 
3.3.2) Ascertaining if cytotoxicity is as a consequence of apoptosis induction 
using the APOPercentageTM assay 
 
Apoptosis may be defined as programmed cell death characterized by certain 
morphological features such as membrane asymmetry and attachment, condensation 
of the chromatin, and internucleosomal cleavage of DNA. In apoptotic cells, the 
membrane phospholipid phosphatidylserine (PS) is externalized to the outer-leaflet of 
the plasma membrane (Fadok et al., 1992). The APOPercentageTM assay is a dye 
uptake assay which stains apoptotic cells with a red dye (Biocolor Ltd). The exposure 
of the PS allows the unidirectional uptake of the APOPercentageTM dye. As a 
consequence only those apoptotic cells that have undergone the externalization of 
phosphatidylserine will be dye labeled, whereas the normal and necrotic cells that are 
present remain unlabelled. 
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Figure 3.2. Neutral red assay demonstrating cytotoxicity (represented by the 
blue graphs) and the APOpercentageTM assay kit demonstrating apoptosis 
(represented by the pink graphs). Cells were treated for 24hrs with increasing 
concentrations (0.625, 1.25, 2.5, 3.75 and 5mg/ml) of plant aqueous extracts on 
the MCF7 cell line.  
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Figure 3.3. Neutral red assay demonstrating cytotoxicity (represented by the 
blue graphs) and the APOpercentageTM assay kit demonstrating apoptosis 
(represented by the pink graphs). Cells were treated for 24hrs with increasing 
concentrations (0.625, 1.25, 2.5, 3.75 and 5mg/ml) of plant aqueous extracts 
on the HeLa cell line.  
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Figure 3.4. Neutral red assay demonstrating cytotoxicity (represented by the blue 
graphs) and the APOpercentageTM assay kit demonstrating apoptosis (represented 
by the pink graphs). Cells were treated for 24hrs with increasing concentrations 
(0.625, 1.25, 2.5, 3.75 and 5mg/ml) of plant aqueous extracts on the CHO cell line.  
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CHO cells were plated in 24 well tissue culture plates as described in section 2.5.2.  
The cells were treated with aqueous extract of all plants used for 24 h. The 
concentrations ranged between 0.625 mg/ml and 5 mg/ml. Cells were treated, 
permeabilized and stained with APOPercentageTM dye, the cells were analyzed on a 
FACScan instrument using CELLQuest PRO software (BD Biosciences). The cell 
fluorescence was measured by flow cytometry using the FL2 channel (565 to 605 nm) 
and a minimum of 10 000 events was acquired per sample. The pro-apoptotic activity 
induced by individual plant extracts are presented on Figure 3.2, 3.3 and 3.4 (in red) 
that represent the MCF7, Hela, and CHO cell lines respectively.  
 
The aqueous extract of C. africanum and E. rhinocerotis display noteworthy pro-
apoptotic activity (above 40 %) in relation to the extracts of the other seven plants 
that display  pro-apoptotic activity below 10% in the breast cancer cell line (MCF7) 
results presented in figure 3.2. The apoptosis induction by C. orbiculata were 
negligible, even at lower concentrations such as 312.5 µg/ml, 156.25 µg/ml and 78.13 
µg/ml (results not shown), thus cell death may be an effect of necrosis. The aqueous 
extract of H. pubescens and E. rhinocerotis displayed the highest pro-apoptotic 
activity (above 40 %) in the cervical cancer cell line (HeLa) results presented in 
figure 3.3. Thus, H. pubescens is the only extract that induced cell death as a 
consequence of apoptosis in the HeLa cell line, as opposed to C. capensis, E. 
mauritanica, C. africanum and C. orbiculata that may be inducing cell death as a 
consequence of necrosis. E. rhinocerotis induced pro-apoptotic activity with 
negligible cytotoxicity. The aqueous extracts of E. mauritanica C. africanum, L. 
frutescens and E. rhinocerotis displayed pro-apoptotic activity (above 40 %) in 
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relation to the extracts of the other five plants in the non-cancerous cell line (CHO) 
results presented in figure 3.4. 
 
The results for the CHO cell line proved that the cytotoxicity test is not reliable as the 
extracts of E. mauritanica C. africanum, L. frutescens and E. rhinocerotis displays 
considerable pro-apoptotic activity but negligible cytotoxicity indicating that these 
plants would have been unduly eliminated in the screening process. The pro-apoptotic 
activity of the nine plants at 5 mg/ml on all three cell lines were further tabulated to 
provide a concise visual representation of results for easy interpretation (see table 
3.3). C. africanum, L. frutescens and E. rhinocerotis extracts induce the highest 
degree of apoptosis for the CHO cell line. Also, the CHO cell line displays the 
highest degree of susceptibility to the nine plant extracts, as opposed to MCF7 that 
displays the least sensitivity. This is to be expected as the CHO cell line is a so called 
'normal' animal cell line that should not have mutations rendering it less resistant to 
apoptosis inducers. Also, MCF7 has been characterized with caspase-3 gene mutation 
(Kurokawa et al., 1999). From the extensive coverage of the most common pathways 
in section 1.3.4 it can be inferred that most of the pathways commonly converge at 
caspase-3. This highlights the reason why the presence of caspase-3 is recognized as a 
hallmark of apoptosis and accounts for the high resistance to apoptosis inducers 
displayed by the MCF7 cell line. C. africanum and E. rhinocerotis extracts display 
the highest degree of activity in the MCF7 cell line. It can thus be deduced that the C. 
africanum and E. rhinocerotis extracts can induce an apoptosis pathway independent 
of caspase-3. H. pubescens, L. frutescens and E. rhinocerotis extracts are the most 
active apoptosis inducers for the HeLa cell line. The HeLa cell line may be more 
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resistant to apoptosis inducers as a consequence of being infected with the human 
papillomavirus (HPV) that synthesizes the protein products E6 and E7. The E6 and 
E7 proteins bind to and inhibit p53 and Rb, thus increasing the HeLa cell line 
resistance to apoptosis pathways involving these genes (Phelps et al., 1991; Scheffner 
et al., 1991). 
  
Table 3.3. Apoptosis activity induced by the nine indigenous South African plants at 
      5 mg/ml. 
 
 
The purpose of this section is to identify a lead compound that would be subjected to 
combinatorial chemistry techniques after characterization to develop a future site 
specific non-toxic anti-cancer drug. Thus, E. rhinocerotis aqueous extract that 
induced considerable pro-apoptotic activity across all the cell lines was tested for 
specific hallmarks of apoptosis and active compounds from it will be purified and 
characterized.  
 
 
        71                             50                          43 E. rhinocerotis 
        31                              6                           31             O. pes caprae 
        24                              6                           30 E. plantagineum 
        34                              7                           34 C.orbiculata 
        71                              8                           41 L. frutescens 
        71                             43                          34 C. africanum 
        34                             6                            43 H.pubescens 
        53                            10                           31 E. mauritanica 
        42                             6                            37 C. capensis 
       CHO                       MCF7                      HeLa   
Apoptosis ( %) Plants 
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3.4) Screening E. rhinocerotis aqueous extract for the ability to induce 
specific markers of apoptosis 
 
 
3.4.1) Externalization of phosphatidylserine (PS)  
 
The characteristic externalization of the phosphatidylserine (PS) is a prominent 
marker of apoptosis. Annexin V-PE Apoptosis Detection assay allows for the 
detection and quantification of the externalized phosphatidylserine (PS) by FACS 
analysis. The Annexin V-PE Detection assay is based on the principle that annexin V, 
the 35-36 kDa Ca2+ dependent phospholipid binding protein, has a strong affinity for 
PS. Annexin V can also be conjugated to fluorochromes such as Phycoerythrin (PE) 
without affecting its affinity for PS, thus making annexin V-PE a sensitive probe for 
apoptosis detection. Externalized PS will thus be fluorescently labeled by annexin V-
PE (Vermes et al., 1995). Results can be acquired and analyzed in the form of a 
histogram or dot plot. For the results obtained in histogram form, normal cells will 
fluoresce in the first decade (101), whilst a fluorescent shift along the x-axis from the 
first decade (101) to the second decade (102) or third decade (103) is expected for 
apoptotic cells.  
 
CHO cells were plated in 24 well tissue culture plates as described in section 2.5.3.  
The cells were treated with aqueous extracts from E. rhinocerotis and known 
apoptosis inducers L. frutescens and staurosporine, stained with annexin V-PE and 
analyzed on a FACScan instrument using CELLQuest PRO software (BD 
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Biosciences). The cell fluorescence was measured by flow cytometry using the FL2 
channel (565 to 605 nm) and a minimum of 10 000 events was acquired per sample.  
 
Less than 2 % of the cells were stained positive for externalized phosphatidylserine in 
the untreated control presented as figure 3.5A. However, as much as 78 % of the cells 
were stained positive for externalized phosphatidylserine in cell treated for 1 hour 
with 1.3 µM staurosporine presented in figure 3.5B. This increase in externalized 
phosphatidylserine is denoted by the shift of the cell distribution to the right into the 
second decade (102), that is, an increase in the fluorescence of PE. The externalized 
phosphatidylserine was also demonstrated in figure 3.5C and 3.5D that represents 
cells that were treated for 6 h with 3.5 mg/ml of E. rhinocerotis and L. frutescens, 
respectively. Extracts of E. rhinocerotis and L. frutescens displayed that 71 % and 93 
% of cells stained positive for externalized phosphatidylserine, respectively, 
compared to the negligible 2 % of the cells in the untreated control. Previous studies 
have shown that L. frutescens contains pro-apoptotic secondary metabolites 
(Chinkwo, 2005; Tai et al., 2004). These results show that E. rhinocerotis also 
contain secondary metabolites with pro-apoptotic activity.  
 
 
3.4.2) Caspase-3 activation   
 
Another prominent hallmark of cells undergoing apoptosis is the activation of  
caspase-3 (reviewed in section 1.3.4). The active Caspase-3 PE Detection assay 
allows for the detection and quantification of active caspase-3 by FACS analysis (BD 
Bioscience). This assay is based on the principle that active caspase-3 is recognized
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 Figure 3.5. Flow cytometry analysis demonstrating the externalization of phosphatidylserine in CHO cells treated 
for 6 h with 3.5 mg/ml of plant aqueous extract. Experiments were repeated in triplicate. Annexin V- PE Apoptosis 
Detection assay results are resented in histogram form, denoting the percentage of cells staining positive (in the M2 
region) for annexin V. A represents the untreated control. B represents the positive control (staurosporine). C 
represents the aqueous extract of L. frutescens. D represents the aqueous extract of E. rhinocerotis.  
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by monoclonal antibodies that were specifically made against the cleaved form of 
caspase-3. The monoclonal antibodies are conjugated with the fluorochrome PE 
(Belloc et al., 2000). Consequently, the apoptotic cells that contain active caspase-3 
will fluoresce. 
 
Cells were plated in 24-well tissue culture plates as described in section 2.5.4.  After 
cells were treated, permealized and stained with PE-conjugated polyclonal active 
caspase-3 antibody, the cells were analyzed on a FACScan instrument. Less than 2 % 
of the cells were stained positive for active caspase-3 in the untreated control 
presented as figure 3.6A. However, a noteworthy 49 % of the cells were stained 
positive for active caspase-3 in the cell treated for 1 h with 1.3 µM staurosporine. 
This increase in active caspase-3 is denoted by the shift of the cell distribution to the 
right into the second decade (102), that is, an increase in the fluorescence of PE. The 
externalized phosphatidylserine was also demonstrated in figure 3.6C and 3.6D that 
represents cells treated for 6 h with 3.5 mg/ml of E. rhinocerotis and L. frutescens, 
respectively. E. rhinocerotis and L. frutescens displayed 50 % and 60 % of cells 
stained positive for active caspase-3, respectively, compared to 2 % of the cells in the 
the untreated cells. These results clearly show that the secondary metabolites from E. 
rhinocerotis induce the activation of caspase-3. In section 3.3 it was demonstrated 
that E. rhinocerotis induces apoptosis activity in the MCF7 cell line that has been 
documented to have caspase-3 gene mutation (Kurokawa et al., 1999), indicating that 
the secondary metabolites in this extract are inducing both caspase dependent and 
caspase independent pathways. 
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 Figure 3.6. Flow cytometry analysis demonstrating the presence of active caspase-3 in CHO cells treated for 6 h 
with 3.5 mg/ml of plant aqueous extract. Experiments were repeated in triplicate. Active caspases-3 PE Detection 
assay results are presented in histogram form, denoting the percentage of cells staining positive (in the M2 region) 
for active caspases-3. A represents the untreated control. B represents the positive control (staurosporine). C 
represents the aqueous extract of L. frutescens. D represents the aqueous extract of E. rhinocerotis. 
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3.4.3) DNA fragmentation  
 
The fragmentation of the genomic DNA is a late event during apoptosis. DNA 
fragmentation is a result of active caspase-3 mediated cleavage of ICAD to activate 
CAD which is responsible for the fragmentation of the DNA (Sakahira et al., 1998; 
Zhao et al., 2001). The APO-DIRECT™ Kit allows for the detection and 
quantification of DNA breaks by FACS analysis. The result of DNA fragmentation 
during apoptosis is the exposure of a multitude of 3'-hydroxyl termini. This 
characteristic can be used to differentiate apoptotic cells from viable cells by labeling 
the DNA breaks with fluorescein isothiocyanate-tagged deoxyuridine triphosphate 
nucleotides (FITC-dUTP). The enzyme terminal deoxynucleotidyl transferase (TdT) 
catalyzes a template-independent addition of deoxyribonucleoside triphosphates to 
the 3' hydroxyl ends of double- or single-stranded DNA (Eschenfeldt and Berger, 
1987). Results has been acquired and analyzed in the form of a histogram or dot plot. 
For the results obtained in histogram format, viable cells fluoresce within the first 
decade (1010-101), whilst apoptotic cells shifts beyond 101. For the results obtained as 
a dot plot, the convention is to display DNA content (Linear Red Fluorescence) on 
the X-axis and the FITC-dUTP (Log Green Fluorescence) on the Y-axis. Acquisition 
of the DNA content parameter allows for discrimination between cells in G1 and G2 
phase of the cell cycle, since cells in G2 phase will have double the DNA content of 
cells in G1 phase. When analyzing DNA content of cells it is important that only 
single cells and not cell doublets or cell clusters are evaluated. To achieve this dual 
parameter analysis (DNA area signal on the Y-axis and DNA width on the X-axis) is 
used to exclude DNA doublet events. Single cells will have a defined area and width, 
while cell doublets and cell clusters will have a much higher area and width. It is 
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therefore possible to identify the cell doublets and cell clusters and exclude them 
from the analysis. Once single cells have been identified and gated, these cells are 
evaluated for FITC-fluorescence. Since only the apoptotic cells are labeled with 
FITC-dUTP these cells will display increased FITC-fluorescence on the Y-axis. 
 
Cells were plated in 6 well tissue culture plates as described in section 2.5.5.  The 
cells were treated, permealized and labelled with F-dUTP using the APO-DIRECT™ 
staining kit. Cells were analyzed on a FACScan instrument using CELLQuest PRO 
software. Less than 2 % of the cells stained positive for F-dUTP in the untreated 
control presented as figure 3.7A. However, 43 % of the cells were stained positive for 
F-dUTP in the cell treated for 24 h with 1.3 µM staurosporine presented in figure 
3.7B. DNA strand breaks were also demonstrated in figure 3.7C and 3.7D that 
represents cells treated for 48 h with 5 mg/ml of L. frutescens and E. rhinocerotis, 
respectively. Extracts of L. frutescens and E. rhinocerotis respectively induce DNA 
fragmentation in 86 % and 75 % of the cells, compared to the 2 % of the cells in the 
untreated cells.  
 
3.3.4) Summary 
 
The aim of this study was to identify plant aqueous extracts with pro-apoptotic 
activity and therefore also anti-cancer activity. These results demonstrate that not all 
plant extracts tested in this study have the potential to induce pro-apoptotic activity. 
Furthermore, it also shows that extracts that are cytotoxic are not necessarily pro-
apoptotic, that is, cell death induced by these secondary metabolites may be a 
consequence of necrotic rather than apoptotic cell death. 
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Figure 3.7. Flow cytometric analysis of DNA fragmentation. CHO cells were treated for 
48 h with 5 mg/ml of plant aqueous extract. Experiments were repeated in triplicate. As 
a positive control cells were treated with 1.3 µM staurosporine. DNA fragmentation 
results are presented as a dot plot and in histogram form. A represents the untreated 
control. B represents the positive control (staurosporine). C represents the aqueous 
extract of L. frutescens. D represents the aqueous extract of E. rhinocerotis.  
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Extracts from C. africanum H. pubescens, L. frutescens and E. rhinocerotis 
demonstrated much higher pro-apoptotic activity than the other five plants. Also, the 
non-cancerous CHO cells were more sensitive to the effects of the plants extracts than 
the cancer cell lines. This is to be expected, since the CHO is not a transformed cell 
line, whereas the cancer cell lines have mutations which make these cells less 
sensitive to apoptosis inducers. E. rhinocerotis and C. africanum are the only plants 
that induce apoptosis in the MCF7 cell line that is characterized with caspase-3 gene 
mutation. This result is notable as most apoptosis inducers require caspase-3 
activation. E. rhinocerotis extract also displays the ability to induce specific markers 
of apoptosis in CHO cells such as such as; phosphatidylserine externalization, 
activation of caspase-3 and DNA fragmentation. This ability of the E. rhinocerotis 
extract to induce activation of caspase-3 in CHO cells and induce apoptosis in the 
MCF7 cell line that is characterized with caspase-3 gene mutation indicates that this 
extract has the ability to induce apoptosis via caspase-3 dependent and caspase-3 
independent pathways respectively.  
   
E. rhinocerotis was selected for further study as it was the only extract that displayed 
notable apoptosis activity across all three cell lines. It also induced specific markers 
of apoptosis and activated more than one apoptosis pathway. This ability to induce 
more than one apoptosis pathway may also suggest the presence of more than one 
apoptosis inducer in the crude E. rhinocerotis extract. 
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CHAPTER 4: INVESTIGATING WHETHER THE 
VARIATION IN BIOACTIVITY WITHIN THE E. 
RHINOCEROTIS SPECIES IS ASSOCIATED WITH 
GENETIC VARIATION 
 
4.1) Introduction 
 
Previous studies demonstrated that the variation in bioactivity within the same plant 
species can be linked to seasonal and geographical variation (Yang and Loopstra, 
2005). For example, it has been demonstrated that extracts for L. frutescens collected 
from different geographical locations display variation in pro-apoptotic activity 
(Chinkwo, 2005). The variation in the bioactivity of plant extracts within the same 
plant species from different geographical locations can be ascribed to the plant 
chemistry, that is, the difference in the composition of the secondary metabolites 
present. It is possible those environmental factors can influence plant chemistry or 
that genetic mutations in the plant can result in genetic variants with different plant 
chemistry. 
 
Several plant extracts were screened for pro-apoptotic activity. It was concluded in 
chapter 3 that not all these plant extracts contain pro-apoptotic activity. Also, E. 
rhinocerotis exhibited the most significant apoptosis activity across all the cell lines 
screened. Therefore, the aim of this section was to compare the bioactivity of E. 
rhinocerotis samples collected from different geographical locations and to determine 
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if there is any genetic variance in this E. rhinocerotis samples collected from the 
different geographical locations that may account for the variation in pro-apoptotic 
activity.  
 
The genetic variation between plants can be illustrated by the construction of 
phylogenetic tree based on the conservation or slow evolution of particular genes 
across species (Alvarez and Wendel, 2003). Phylogenetic relationships among 
congeneric species and closely related genera in Asteraceae have been elucidated by 
DNA sequence analysis of the internal transcribed spacer (ITS) of nuclear ribosomal 
DNA (nrDNA) (Samuel et al., 2003). This study by demonstrates that the 
phylogenetic analysis based on the ITS regions provide higher resolution compared to 
the phylogenetic analysis based on the maternally inherited trnL intron, trnL/F spacer, 
and matK sequence (Samuel et al., 2003). To date only the trnL/F spacer of E. 
rhinocerotis has been sequenced for phylogenetic studies; at the Australian National 
University, Division of Botany and Zoology (Bayer et al., 2000). 
 
The degree of pro-apoptotic activity present in E. rhinocerotis from different 
geographical locations was determined by the APOPercentageTM assay. The 
investigation into the presence of genetic variance was determined by the 
amplification of the ITS1 region using the universal primers ITS5 and ITS2 (White et 
al., 1990).  
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4.2) Pro-apoptotic activity of E. rhinocerotis from different 
geographical location 
 
E. rhinocerotis was collected from various places in the Western Cape, namely 
Blaauwberg, Helderberg, Tygerberg, Kirstenbosch and Tulbagh. Aqueous extractions 
of these plants were performed as described in section 2.7.1. CHO cells were plated 
in 24-well tissue culture plates as described in section 2.5.2.  The cells were treated 
with 5 mg/ml aqueous extract for 24 h. After the cells were treated and stained with 
APOPercentageTM dye, the cells were analyzed on a FACScan instrument. The 
results were plotted as a bar graph with the apoptosis activity on the Y-axis and the 
fractions on the X-axis.  
 
Figure 4.1 illustrated that for the untreated control less then 2 % of the cells were 
positive for apoptosis, whilst staurosporine induced apoptosis in 78 % of the cells. 
The fractions from Blaauwberg, Helderberg, Tygerberg, Tulbagh and Kirstenbosch 
induced apoptosis in 42 %, 57 %, 51 %, 71 % and 7 % of the cells, respectively. This 
results show that there was a notable variance (7% to 71%) in the bioactivity of E. 
rhinocerotis collected from the different geographical locations. The extract from the 
plant material collected from Kirstenbosch showed the lowest activity, whilst the 
extract from the plant material collected from Tulbagh showed the highest pro-
apoptotic activity. 
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Figure 4.1 Flow cytometric analysis of the E. rhinocerotis extracts from different 
geographical locations by APOpercentageTM staining. CHO cells were treated for 
24 h with 5 mg/ml of E. rhinocerotis collected from different geographical locations. 
Experiments were repeated in triplicate. As a positive control cells were treated with 
1.3 µM staurosporine. The results were plotted on a bar graph with apoptosis activity 
on the Y-axis and the E. rhinocerotis extracts on the X-axis. The reddish-pink bar 
indicates the fraction that displayed the highest pro-apoptotic activity. 
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4.3) Genetic study 
 
4.3.1) Cloning ITS1 into pGEM® –T Easy vector 
 
The gDNA of E. rhinocerotis collected from Blaauwberg, Helderberg, Tygerberg, 
Kirstenbosch and Tulbagh were extracted as described in section 2.6.1. The extracted 
gDNA was electrophoresed on an agarose gel to assess the quality of the DNA. 
Figure 4.2 illustrated that all the samples had high molecular weight intact fragment. 
 
ITS1 was amplified by PCR using the forward primer ITS5 and reverse primer ITS2 
as described in section 2.6.2. The amplification of ITS1 was verified by agarose gel 
electrophoresis. Figure 4.3 showed the PCR amplification of ITS1. The negative 
control displayed no traces of contaminating DNA. For each DNA sample 
(representing the different geographical locations) a single fragment of + 370 bp was 
amplified.  
 
The PCR products were purified as described in section 2.6.4. The purified ITS1 
products were cloned into pGEM-T easy vector as described in section 2.6.5. The 
transformed colonies were screened for the presence of the insert as described in 
section 2.6.6. Figure 4.4 showed the colony PCR screen for the presence of the ITS1 
insert. The negative control displayed no traces of contaminating DNA. For each 
geographical location, four single colonies were screened. Figure 4.4 shows that all 
the colonies screened were positive for the presence of the ITS1 fragment. As 
expected the PCR products were bigger than the original ITS1 fragment, since M13
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Figure 4.2 Agarose gel electrophoretic representation of the gDNA extracted from the 
E. rhinocerotis plants collected from different geographical locations. The gDNA 
extracted are indicated on the figure. 
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Figure 4.3 PCR screening for the presence of the ITS1 sequence of E. rhinocerotis 
plants collected from different geographical locations. The amplified ITS1 
sequences are indicated on the figure. 
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 Figure 4.4 Colony PCR screening for the presence of the ITS1 sequence of E. rhinocerotis plants 
collected from different geographical locations. Four random colonies were screened from each 
geographical location. The different geographical locations are indicated on the figure.  
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primers were used for the colony PCR screen. Glycerol stocks of the positive clones 
were prepared. These positive PCR clones were also sequenced by Inqaba 
Biotechnical Industries (Pty) Ltd. For each plant one colony was selected and 
sequenced in both the forward (5' to 3') and reverse (3' to 5') orientation. 
 
 
4.3.2) Phylogenetic analysis of ITS1  
 
The ITS1 sequences were aligned with the sequencing alignment programme, 
ClustalX. Figure 4.5 shows the aligned sequences from the different geographical 
locations. Alignment homology ranged between 100 % and 98 %. Single nucleotide 
polymorphisms (SNP) were found at position 156 (T/C), 179 (C/A), 180 (T/C), 196 
(G/T) and 297 insT for the Kirstenbosch sequence. Also, a SNP was found at position 
170 (T/C) and 297 insT for the Blaauwberg sequence and a SNP was found at 
position 52 (C/T) and a deletion was found at positions 17 delG and 390 delT for the 
Helderberg sequence. Deletions were also found at positions 5 delA, 23 delG, 390 
delT.  
 
Sequences that are homologous to the five ITS1 sequences were retrieved using 
BLAST. The homologous sequences retrieved were all members of the Asteraceae 
family. These homologous sequences and the five ITS1 sequences were re-aligned 
using Geneious software. A phylogenetic tree of the re-aligned data was constructed 
using Geneious software with 1000 bootstraping and the Jukes Cantor genetic 
distance model by Neighbor-Joining method. Figure 4.6 shows the phylogenetic tree 
of the re-aligned sequences. The phylogenetic tree indicates that there are basically 5  
  
 

  
 
 
 
 
 
Figure 4.5 Sequence alignment of the ITS1 sequences of the E. rhinocerotis plants 
collected from different geographical locations. Dissimilarities are indicated by the 
colour (       ) break in the green similarity sequence. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Phylogenetic tree of the aligned ITS1 sequences of the E. rhinocerotis plants 
collected from different geographical locations and homologous sequences that were 
retrieved using Blastn. The different geographical locations are Helderberg, Tygerberg, 
Blaauwberg, Kirstenbosch and Tulbagh.  
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groups emerging from the root. Of the homologous sequences generated by BLAST, 
P. serpyllifolia is most similar to the E. rhinocerotis consensus sequence.   
 
Also, the E. rhinocerotis sequences representing the different geographical locations 
are diverging at different times, which highlighting their genetic variance. The 
Tulbagh sequence is most analogous to the root sequence, trailed by the Tygerberg 
sequence, the Helderberg and Blaauwberg sequence. The Blaauwberg sequence and 
the Kirstenbosch sequence diverge at the same time point. The variation in ITS1 
sequences in the same species is very significant. Thus, this preliminary data suggest 
genetic variation. 
 
 
4.4) Summary 
 
It has been established that the degree of pro-apoptotic activity present in E. 
rhinocerotis from different geographical locations differ significantly. The 
Kirstenbosch extract displays the least activity (7%), whilst the Tulbagh extract 
displays the most activity (71%). If this variation in pro-apoptotic activity correlates 
to the genetic variation, it propagates that a link may exist as genetic variation is 
responsible for differences in plant chemistry.  
 
The ITS1 sequence was successfully amplified with the universal primers ITS5 and 
ITS2; and cloned into the pGEM-T easy vector for sequencing. The sequence 
alignment displayed 100 % to 98 % homology, which denotes significant variation in 
the same species. When comparing the genetic variation of the ITS1 sequences with 
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their corresponding levels of apoptosis activity that is; Tulbagh (71%), Tygerberg 
(57%), Helderberg (51%), Blaauwberg (42%) and Kirstenbosch (7%); a pattern 
emerges; the degree of pro-apoptotic activity decreases, the more the sequence 
deviates from the root sequence. This preliminary data suggest a link between the 
genetic variation and pro-apoptotic activity. However, the difference in genetic 
variation highlights the possibility that the difference may be as a consequence of 
subspecies variation. Also, more than one colony should be sequenced from each 
colony PCR plate to ensure accuracy and a larger sample it required, along with other 
Elytropappus species to establish statistical significance. 
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CHAPTER 5: THE PARTIAL PURIFICATION OF THE 
PRO-APOPTOTIC SECONDARY METABOLITE/S 
ISOLATED FROM E. RHINOCEROTIS  
 
5.1) Introduction 
 
In chapter 4 it was concluded that the aqueous extract of E. rhinocerotis collected 
from Tulbagh contains a secondary metabolite(s) with pro-apoptotic activity. 
Therefore, the aim of this section was to isolate and characterize this compound(s). 
Bio-activity guided fractionation was used to trace the isolation of the pro-apoptotic 
metabolite(s). Fractionation involves the separation of a mixture of metabolites based 
on their molecular structures and intermolecular forces (Robards et al., 2002). 
Examples of separation technology that use these principles to separate molecules 
are; organic extraction, Liquid Column Chromatography (LCC), Thin Layer 
Chromatography (TLC) and High Performance Liquid Chromatography (HPLC). At 
each fractionation step bio-assays were used to identify the fraction containing the 
highest activity and therefore the secondary metabolite(s) of interest (Sezik et al., 
2005; Wu et al., 2003). 
 
Purification of secondary metabolites from plant extracts can be an expensive and 
time consuming process that requires the consideration of many possible problem 
areas to ensure its success. For example; it is possible that the bio-activity observed in 
total extracts, is as a consequence of multiple metabolites acting in a synergistic 
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fashion. The separation of such secondary metabolites by fractionation will result in 
reduced or lost bio-activity. Furthermore it is expected, that a portion of the 
secondary metabolites of interest will be sacrificed during the fractionation process. 
To maintain a reasonable level of purity, only the fraction with the highest activity 
will be further processed. The less active fractions can be reprocessed to recover more 
active material, but these fractions, also contain other non-bioactive secondary 
metabolites/'impurities' that may be re-introduced into the more active fraction. The 
purity of the active, unknown secondary metabolite is of paramount importance as the 
99 % pure product may not be responsible for the major activity but rather the 1 % of 
'impurity'. This is highly probable especially if the 'impurity' is an analog of the major 
secondary metabolite. This dilemma may be bypassed by using synthetic chemistry to 
produce an array of analogs of the major secondary metabolite that can be screened 
comparatively for apoptosis activity and consequently the analog responsible for the 
major activity can be identified. It must also be noted that NMR and X-ray 
crystallography requires at least 95 % and 99 % purity, respectively (Cannell, 1998). 
NMR and X-ray crystallography also require a specific yield of 'pure' compound for 
structure determination. The yield obtained at the end of the fractionation process 
may be insufficient for NMR or X-Ray analysis. This problem can be 
circumnavigated by starting the isolation process with a higher yield of total extract. 
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5.2) Organic extraction used to fractionate the aqueous extract from E. 
rhinocerotis   
 
The wide array of secondary metabolites extracted by aqueous extraction, provide a 
platform from which the secondary metabolites can be fractionated or separated by 
organic extraction. In principle, organic extraction separate secondary metabolites 
based on increasing polarity (Ohno et al., 2005).  
 
An aqueous extract of 1 kg dried plant material was prepared.  The aqueous 
extraction yielded 2 000 ml extract at 40 mg/ml. The 2 000 ml aqueous extract was 
fractionated by organic extraction as described in section 2.7.2. The solvents used in 
the organic fractionation process were acetone, n-butanol, ethyl acetate, chloroform 
and petroleum ether. The organic fractions were dried by rotary evaporation and re-
dissolved in methanol.  
 
Methanol is toxic to cells. Hence, a methanol dose response was used to determine 
the minimum methanol concentration that would not affect the cells. Cells were 
plated in 96-well tissue culture plates and exposed to methanol with concentrations 
ranging between 0.5 % and 8 % for 48 h. After the cells were treated and stained with 
APOPercentageTM dye, the trapped dye was released from the cells and quantified by 
colorimetric measurement. The results were plotted as a bar graph with absorbance at 
550 nm on the Y-axis and the percentage methanol on the X-axis. Figure 5.1 shows 
that methanol concentrations of up to 1 % did not induce apoptosis. At these 
concentrations no morphological changes were observed. Methanol concentrations 
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Figure 5.1. Flow cytometric analysis of the effects of methanol using the 
APOPercentageTM assay. CHO cells were treated for 48 h with 0.5 %, 1 %, 2 %, 4 % 
and 8 % methanol. As a positive control, cells were treated with 1.3 µM staurosporine. 
The experiment was repeated in triplicate. The results were plotted on a bar graph with 
apoptosis activity on the Y-axis and the concentration of methanol on the X-axis. The 
reddish-pink bar indicates the fractions that displayed the highest pro-apoptotic 
activity. 
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between 2 % and 8 % caused changes in cell shape and size which were accompanied 
by increased levels of apoptosis. This result shows that the methanol concentration of 
0.5 % will not have any adverse affects on the cells. Hence, in subsequent 
experiments the final methanol concentrations were maintained below 0.5 %. 
 
The organic extracts were prepared at 40 mg/ml dissolved in 10% methanol. Cells 
were plated in 24-well tissue culture plates as described in section 2.5.2 and treated 
with 2 mg/ml of each fraction for 24 h. As a positive control, cells were treated with 
1.3 µM staurosporine for 1 h. Following treatment, cells were stained with 
APOPercentageTM dye and analyzed on a FACScan instrument. The results were 
plotted as a bar graph with the apoptosis activity on the Y-axis and the fractions on 
the X-axis. Figure 5.2 shows that no significant levels of apoptosis activity were 
detected for the untreated and methanol controls. However, 78 % of the cells treated 
with staurosporine stained positive for apoptosis, whilst the chloroform, n-butanol, 
ethyl acetate, petroleum ether, and the remaining aqueous fraction induced apoptosis 
in 52 %, 60 %, 11 %, 20 % and 12 % of the cells, respectively. The chloroform and n-
butanol fractions demonstrated notable apoptosis activity. The n-butanol (nB) fraction 
was selected for further fractionation by LCC.  
 
 
5.3) Chromatography 
 
Chromatography comprises of two phases; the stationary phase and the mobile phase. 
The extract to be fractionated is bound to the stationary phase to which a continuous 
mobile phase is supplied. This allows for the separation of the extract into discrete 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Flow cytometric analysis of the organic fractions by 
APOPercentageTM staining. CHO cells were treated for 24 h with 2 mg/ml of each 
organic fraction. As a positive control, cells were treated with 1.3 µM 
staurosporine. The experiment was repeated in triplicate. The results were plotted 
on a bar graph with apoptosis activity on the Y-axis and the fractions on the X-
axis. The reddish-pink bar indicates the fraction that displayed the highest pro-
apoptotic activity. 
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fractions through the stationary phase. The secondary metabolites distribute between 
the two phases which depend on their relative affinities for the phases, as determined 
by molecular structures and intermolecular forces (Robards et al., 1994). Thus, the 
secondary metabolites with a lower affinity for the stationary phase will separate 
more rapidly. This differential migration rate of the secondary metabolites, results in 
their separation through the system. Separation would further be affected by; the 
nature of the two phases, the temperature and the velocity of the mobile phase. 
(Robards et al., 1994). 
 
5.3.1) Thin Layer Chromatography (TLC) 
 
TLC is a simple and rapid separation technology which has modest demands on 
equipment resources and has the added advantage of being able to separate a larger 
sample capacity than HPLC. This technique only requires the TLC plate, solvent and 
a suitable container for development. Evaluation of the plate is feasible with the 
naked eye, spray reagents and ultra violet (UV) light at specific wavelengths. TLC 
separates the extract based on polarity and the liquid phase mobilizes as a result of 
capillary action. TLC is also used to determine the mobile phase required for product 
separation by LCC (Cannell, 1998).  
 
 
5.3.2) Liquid Column Chromatography (LCC) 
 
Although LCC is more complex and time consuming than TLC, it has the added 
advantage of being able to separate a larger sample capacity than TLC and has 
modest demands on equipment resources. The stationary phase in LCC may be 
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packed into a glass or metal column, to which a mobile phase is continuously 
supplied. The size of the column used depends on the volume of material separated 
and the degree of separation required. In column chromatography the liquid phase 
mobilizes as a result of gravity as apposed to TLC which makes use of capillary 
action. Detection methods that can be used include UV light, GC-MS, NMR and 
numerous bioactivity guided assays (Cannell, 1998). 
 
TLC demonstrated that ethyl acetate:hexane (1:3) is the mobile phase required to 
separate the active nB fraction into discrete fractions (results not shown) (Miceli et 
al., 2005; Sezik et al., 2005). The active nB fraction was fractionated by LCC as 
described in section 2.7.4. The LCC fractions were dried by rotary evaporation and 
re-dissolved in methanol. Cells were plated in 24-well tissue culture plates as 
described in section 2.5.4 and treated with 0.50 mg/ml of each fraction for 24 h. After 
cells were treated and stained with APOPercentageTM dye, the cells were analyzed on 
a FACScan instrument. The results were plotted as a bar graph with the apoptosis 
activity on the Y-axis and the fractions on the X-axis. Figure 5.3 shows that for the 
untreated control less than 2 % of the cells were positive for apoptosis, whilst 
staurosporine induced apoptosis in 88 % of the cells. The nB fraction was separated 
into 9 fractions by LCC. The following fractions: nB 1 and nB 2 were combined as 
the concentrations of these fractions were at least 10 times less than the 
concentrations obtained for the other fractions. The fractions nB 1+2, nB  3, nB  4, 
nB 5, nB 6, nB 7, nB 8 and nB  9 induced apoptosis in  2 %, 3 %, 5 %, 19 %, 72 %, 
87 %, 35 % and 33 % of the cells, respectively. Fractions nB 6 and nB 7 
demonstrated notable pro-apoptotic activity. These successive fractions were 
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Figure 5.3. Flow cytometric analysis of the LCC fractions by APOPercentageTM 
staining. CHO cells were treated for 24 h with 0.50 mg/ml of each LCC fraction. 
As a positive control, cells were treated with 1.3 µM staurosporine. Experiment 
was repeated in triplicate. The results were plotted on a bar graph with apoptosis 
activity on the Y-axis and the fractions on the X-axis. The reddish-pink bar 
indicates the fraction that displayed the highest pro-apoptotic activity. 
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combined to form fraction nB 67. The Rf of the active nB 67 fraction ranged between 
0.1 and 0.44. The active nB 67 fraction was selected for further fractionation by TLC.  
The active nB 67 fraction was further fractionated on the glass TLC plates as 
described in section 2.7.3.2. The solvent system utilized was ethyl acetate : hexane in 
a 1 : 9 ratio. This solvent system was determined using TLC aluminium sheets as 
described in section 2.7.3.1. The TLC fractions were dried by rotary evaporation and 
re-dissolved in methanol. Cells were plated in 24-well tissue culture plates as 
described in section 2.5.4.  The cells were treated with 0.25 mg/ml of each fraction 
for 24 h. After cells were treated and stained with APOPercentageTM dye, the cells 
were analyzed on a FACScan instrument. The results were plotted as a bar graph with 
the apoptosis activity on the Y-axis and the fractions on the X-axis. Figure 5.4 shows 
the untreated and methanol controls induce apoptosis in less than 1 % of the cells and 
that staurosporine induces apoptosis in 74 % of the cells. The active nB 67 fraction 
was fractionated into 5 fractions by TLC. The fractions nB 67.1, nB 67.2, nB 67.3, nB 
67.4 and nB 67.5 induced apoptosis in 5 %, 82 %, 5 %, 11 % and 5 % of the cells, 
respectively. Only fraction nB 67.2 demonstrate significant apoptosis activity. The Rf 
of the active nB 67.2 fraction ranged between 0.15 and 0.24. The active nB 67.2 
fraction was selected for further fractionation by HPLC.  
 
 
5.3.3) Reverse-Phase High Performance Liquid Chromatography 
 
Compared to TLC and LCC; HPLC is more complex, time consuming, has a small 
sample capacity and requires more expensive equipment resources. HPLC is 
exceptional for quantification of compounds and resolution between similar 
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Figure 5.4. Flow cytometric analysis of the TLC fractions by APOPercentageTM 
staining. CHO cells were treated for 24 h with 0.250 mg/ml of each TLC fraction. 
As a positive control, cells were treated with 1.3 µM staurosporine. The 
experiment was repeated in triplicate. The results were plotted on a bar graph with 
apoptosis activity on the Y-axis and the fractions on the X-axis. The reddish-pink 
bar indicates the fraction that displayed the highest pro-apoptotic activity. 
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compounds. With HPLC a sample is separated on the basis of polarity and the liquid 
phase mobilizes as a result of the liquid phase being pumped through the column at 
high pressure (Robards et al., 1994). Samples were fractionated using the Beckman 
HPLC system in combination with the chromatography station with Windows 
ClarityTM DataApex and collected using the FOXY JR 202F20077 fraction collector.  
 
Fraction nB 67.2 was further fractionated by HPLC as described in section 2.6.5. The 
HPLC fractions were dried by rotary evaporation and re-dissolved in 10% methanol. 
Cells were plated in 24-well tissue culture plates as described in section 2.5.4.  The 
cells were treated with 0.025 mg/ml of each fraction for 24 h. After cells were treated 
and stained with APOPercentageTM dye, cells were analyzed on a FACScan 
instrument. The results were plotted as a bar graph with the apoptosis activity on the 
Y-axis and the fractions on the X-axis. Figure 5.5 show that the untreated control 
induces apoptosis in less than 4 % of the cells, whilst staurosporine induces apoptosis 
in 67 % of the cells. The active nB 67.2 fraction was fractionated in 7 fractions by 
HPLC (Figure 5.6C). The fractions nB 67.2.1, nB 67.2.2, nB 67.2.3, nB 67.2.4, nB 
67.2.5, nB 67.2.6 and nB 67.2.7 induced apoptosis in 2 %, 72 %, 39 %, 10 %, 7 %, 2 
% and 3 % of the cells, respectively. Fraction nB 67.2.2 demonstrated the most 
significant apoptosis activity. Purification of the active fractions identified in this 
fractionation process can be monitored by HPLC, whilst the success of each 
fractionation step is screen by serial dilution (Cannell, 1998).  
 
The E. rhinocerotis fractionation process was tracked by HPLC utilizing the 
parameters described in section 2.6.5. Figure 5.6 A represents the active organic 
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fraction (nB). B represents the active LCC fraction (nB 67). C represents the active 
TLC fraction (nB 67.2.) D represents the active HPLC fraction (nB 67.2.2). The 
chromatograph traces provides a visual presentation of the complexity of the different  
subfractions. Figure 5.6 illustrates how the number of secondary metabolites is 
reduced during the chronological fractionation steps. The final fraction, nB 67.2.2  is 
a single peak that may not necessarily be pure as it may consist of a group of 
extremely similar compounds.  
 
Serial dilutions of each active fraction identified in the bioactivity-guided 
fractionation process was tested to determine the concentration of extract required to 
induce apoptosis in 50 % of cells over a period of 24 h i.e. the LD50. Cells were plated 
in 24-well tissue culture plates as described in section 2.5.4.  The cells were treated 
with varying concentrations for 24 h. After cells were treated and stained with 
APOPercentageTM dye, the cells were analyzed on a FACScan instrument. It can be 
assumed that the aqueous extract contains 100 % of the bioactive units before 
fractionation. Tables 5.1 show that during the successive fractionation steps the 
percentage of bioactive units in the total starting extract (one bioactive unit is 
equivalent to the LD50 concentration) decreased from 100 % to 7.5 % in the active 
HPLC fraction nB 67.2.2. This is to be expected since it can be anticipated that at 
each fractionation step bioactive metabolites will be lost. In contrast, the LD50 
determined for each active fraction (results not shown) decreased from 3 mg/ml to 
0.01 mg/ml, indicating an increase in bioactive unit concentration in the active 
fraction. This implies the successful fractionation and purification of the bioactive 
secondary metabolite(s).
                       
7.52000102000.012HPLC
308000402000.0255TLC
6016000404000.0520LCC
752000050040140Organic
extraction 
10026667200013.3340Aqueous       
extraction
 %active 
units 
retained
Total 
unitsVolume (ml)
Units of 
activity per 
40 mg/ml
LD50 
(mg/ml)
Conc. of 
stock 
(mg/ml)
Level
Table 5.1 Serial dilutions of the active fractions used to verify the success of the purification process. 
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The verification of a successful purification process by serial dilution and the HPLC 
chromatograph trace of fraction nB 67.2.2 displaying a single peak, warranted an 
attempt at structure determination by MS/NMR, similar to the strategy used by Sezik 
et al., (Sezik et al., 2005).  
 
 
5.4) Structure Determination 
 
The sample was sent to the Department of Chemistry, University of Stellenbosch, for 
structure determination. The sample was dissolved in CDCl3 and the spectra run on a 
600 MHz Varian Inova NMR spectrometer. The 1H, 13C, 1H-1H COSY, 1H-13C HSQC 
and 1H-13C HMBC NMR spectra was collected. The sample concentration was low as 
can be seen from the 13C NMR spectrum (Figure 5.7) and the HMBC spectrum 
(Figure 5.8) in which only weak correlations were observed. The 1H spectrum (Figure 
5.9) appeared promising with an acid proton being observed at 12 ppm, a number of 
aromatic peaks between 6.5 and 7.5 ppm (which included a para-substituted phenyl 
ring) and probably methoxy CH3’s slightly upfield of 4 ppm and peaks at 2.8, 3.1, and 
5.4 ppm appeared to belong to a single spin system as seen from the COSY spectrum. 
However, integration of the 1H spectrum indicated that it was probably unlikely that 
the para-substituted phenyl ring for instance would be in the same molecule as the 
spin system of the peaks at 2.8, 3.1, and 5.4 ppm. Integrations of other peaks also 
appeared anomalous. From the 1H-13C HSQC spectrum (Figure 5.10) it was seen that 
though some of the signals in the 1H spectrum that appeared to be due to single CH’s 
(5.4 and 6.1 ppm for instance), they were infact due to at least two groups as they 
corresponded to two carbons in the 13C NMR spectrum. It is thus clear that a number 
  
                           
 Figure 5.7: 13C NMR spectrum 
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 Figure 5.10: 1H-13C hsqc NMR spectrum 
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of compounds were present in the sample. This should not necessarily be a barrier to 
elucidating structures of some of these compounds. However, it was found that the 
compounds were very similar resulting in overlapping peaks (especially in the 1H 
spectrum) that made distinguishing the compounds from one another impossible. 
Also, the low concentration of the sample presented difficulties in that the HMBC 
spectrum did not show as many correlations as would be required to unambiguously 
assign the spectrum. Some attempt at structure elucidation was however carried out. 
 
As mentioned above, the presence of a para-substituted phenyl ring was clearly 
observable from the 1H spectrum. From the HSQC and HMBC spectra it was possible 
to identify the carbons on this ring as well (these have been indicated in the 1H and 
13C spectra). The shift of one of the quaternary carbons on the ring was significantly 
downfield at 156 ppm indicated it was likely this carbon was connected to an electron 
withdrawing group such as an -OH. A long range correlation in the HMBC spectrum 
from the phenyl proton at 7.4 ppm to a peak in the 13C spectrum at 79 ppm indicated 
the other substitution on the phenyl ring was a CH probably attached to an O atom 
(this region is typical of such carbons). The proton attached to this carbon resonates at 
5.4 ppm in the 1H spectrum (as determined from the HSQC spectrum). From the 1H-
1H COSY (Figure 5.11) this proton coupled to two diastereotopic protons 2.8 and 3.1 
ppm. Their being diastereotopic was clear from the HSQC spectrum as they both 
showed correlations to the same carbon at 43.2 or 43.4 ppm. Two shifts are given 
here as this is an instance where two different compounds appeared to be resonating 
at the sample position in the 1H spectrum (indeed as mentioned above the integrals of 
the phenyl protons are not in the correct ratio to these protons). Two carbons are seen
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                          Figure 5.11: 1H-1H cosy NMR spectrum
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in the 13C spectrum both correlating to both of the 1H signals, i.e. two diastereotopic 
CH2 groups due to similar molecules. The protons at 3.1 ppm showed a long range 
correlation to a C=O peak in the HMBC spectrum, the 13C chemical shift being 196 
ppm. At this point no more correlations could be followed to complete the possible 
structure of this molecule in the mixture. Thus from the information gathered it 
appeared that a structure similar to the one given below was perhaps a possibility 
(numbering is arbitrary) (Figure 5.12). The predication that it would be a six-
membered ring attached to the phenyl moiety rather than a branched chain is due to 
the chemical shift of C6 being downfield of what would be expected for a chain. 
Unfortunately, no other possible clear structures could be elucidated from the spectra 
especially as no mass spectral data could be obtained that could have been correlated 
with the NMR data. 
 
Figure 5.12:  Compound structure 6-(4´-hydroxyphenyl)-2,3-di(R)tetrahydro-4H-
pyran-4-one elucidated by NMR data. 
 
Further purification is necessary for the assignment of two side chains and elucidation 
of the other compound/s. This may be possible by further purification of the active 
fraction by HPLC using a different column namely, the Thermo Hypersil-keystone 
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hypercarb (250 x 4.6 mm, 5 µ) or attempting to grow crystals from the active extract. 
Once these side chains are known, the apoptosis activity of this synthesized 
compound (if novel) or commercially available compound must be verified. 
 
 
5.3) Summary 
 
The aim of this section was to purify the pro-apoptotic secondary metabolite(s) in the 
aqueous extract of E. rhinocerotis by bio-activity guided fractionation.  
 
These results demonstrated that the aqueous extract can be used as a platform from 
which the secondary metabolites can be fractionated on the basis of increasing 
polarity i.e. by organic extraction. The highest activity resided in the n-butanol 
fraction. N-butanol has a polarity index of 4, thus the active constituent(s) is non-
polar. This active organic fraction was further fractionated by numerous 
chromatographic separation techniques namely LCC, TLC and HPLC respectively. 
The active n-butanol (nB) fraction was fractionated by LCC using ethyl 
acetate:hexane (1 : 3) as the mobile phase. The n-butanol fraction was fractionated 
into 9 fractions of which the successive fractions 6 and 7 were the most active 
fractions. The fractions were combined to form active fraction nB 67. The Rf of the 
active nB 67 fraction ranged between 0.1 and 0.44. Active LCC fraction nB 67 was 
further fractionated by TLC using ethyl acetate : hexane (1 : 9) as the mobile phase. 
The nB 67 fraction was fractionated into 5 fraction of which fraction nB 67.2 was the 
most active fraction. The Rf of the active nB 67.2 fraction ranged between 0.15 and 
0.24. Active TLC fraction nB 67.2 was further fractionated by HPLC as described in 
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section 2.7.5.   The nB 67.2 fraction was fractionated into 7 fractions of which 
fraction nB 67.2.2 was the most active fraction. The sequence of the chromatographic 
separation techniques is of utmost importance as a high yield of total aqueous extract 
is essential in ensuring that sample volume is sufficient for structure determination. 
Thus, the first chromatographic separation was by LCC which allows for the 
separation of a large volume of material, followed by TLC that separates a smaller 
volume but allows for the easy separation of dissimilar groups of compounds and 
HPLC that can further separate the similar compounds in the concentrated active TLC 
extract. This process has successfully transformed a complex mixture of secondary 
metabolites represented by numerous peaks on a chromatograph to a single peak. This 
single peak warranted an attempt at structure determination by NMR.  
 
Integration of the spectra revealed that many similar compounds were present in the 
HPLC sample represented as a single peak on a chromatograph. However, only one 
structure could be partially elucidated as 6-(4´-hydroxyphenyl)-2,3-di(R)tetrahydro-
4H-pyran-4-one, the mixture of compounds were very similar. Also, no quality MS 
data could be generated for correlation with the NMR data as a result of the mixture 
of compounds (MS data not shown). Further purification is necessary for the 
assignment of two side chains. This may be possible by purification of the active 
fraction by HPLC and /or the growing of crystals for structure determination by 
crystallography. 
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CHAPTER 6: GENERAL DISCUSSION 
 
6.1) Introduction 
 
The cell cycle is regulated by cell cycle check points. Genetic mutations that result in 
dysregulation of the cell cycle can lead to the uncontrolled growth of cells. Under 
normal physiological conditions the uncontrolled growth of cells that is tissue 
homeostasis is regulated by apoptosis. One of the physiological roles of apoptosis is 
to orchestrate the elimination of mutated or damaged cells. Cancer arises when cells 
escape the induction of apoptosis due to secondary mutations in genes that regulate 
apoptosis. It is therefore not surprising that the unifying concept for the mechanism of 
chemoprevention is the induction of apoptosis by chemotherapeutic drugs. 
 
Many anti-cancer drugs are derived from natural sources, including marine, microbial 
origin and plants. FDA approved plant derived drugs include Combretastatin A-4 
phosphate (Combretum caffrum), Taxol (Taxus brevifolia), Velban (Catharanthus 
roseus) etc. Thus, the aim of this study was to screen extracts of nine indigenous 
South African plants for the presence of pro-apoptotic compounds. Some of these 
plants are used in traditional medicine to treat cancer. The approach exploited was to 
extract the plant secondary metabolites by aqueous extraction followed by the 
screening of these aqueous extracts using a cytotoxicity assay and numerous 
apoptosis assays namely; the APOPercentageTM assay, Annexin V-PE Detection 
assay, Active Caspase-3 Detection assay and the TUNEL assay. Any secondary 
metabolite that has pro-apoptotic activity can be a potential anti-cancer agent. Hence, 
 88 
the aqueous extract displaying the highest pro-apoptotic activity was selected for 
bioactivity guided fractionation. The fractionation or separation technology used 
includes organic extraction, LCC, TLC and HPLC.   
 
 
6.2) Screening extracts of indigenous South African plants for the 
presence of anti-cancer compounds.  
 
Pharmacological and phytochemical insights into several plants have led either to the 
discovery of novel chemicals and therefore novel drugs or to novel chemicals that 
served as lead compounds for the design of new drugs. In this study nine indigenous 
South African plants were screened; the poisonous Cotyledon orbiculata, Oxalis pes 
caprae, Echium plantagineum, Cissampelos capensis, Euphorbia mauritanica, 
Haemanthus pubescens, Cynanchum africanum as well as the non-poisonous 
Lessertia frutescens and Elytropappus rhinocerotis for the ability to induce pro-
apoptotic activity in the human cancer cell lines (MCF7 and HeLa), and the 'normal' 
hamster cell line (CHO).  
 
Cytotoxicity and cell viability assays have been used extensively to screen potential 
anti-cancer drugs. These assays measure cell death or inhibition of cell growth. The 
rationale is that potential anti-cancer drugs will either inhibit cancer cell growth or 
kill cancerous cells (Cardellina et al., 1993). Noteworthy is the fact that these assays 
do not discriminate between toxic cell death and cell death induced by apoptosis. As a 
consequence many potential anti-cancer drugs which start out as good candidate 
drugs based on cytotoxic and cell viability assays turn out to be too toxic to normal 
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cells and can therefore not be used as anti-cancer agents. This study did not only 
investigate the cytotoxic effects of the plant extracts, but also investigated their pro-
apoptotic activity. In this study, apoptosis was detected and quantified by the 
APOPercentageTM assay whilst cytotoxicity was measured by the NR assay. E. 
mauritanica, C. africanum, L. frutescens and E. rhinocerotis displayed significant 
apoptosis activity but negligible cytotoxicity indicating that these plants would have 
been unduly eliminated as potential sources of anti-cancer agents if the initial 
preliminary screening process was based on cytotoxicity only.  
 
The CHO cell line was more susceptible to the nine plant extracts, than the MCF7 and 
HeLa cell line. The results shows that C. africanum and E. rhinocerotis displayed the 
highest degree of activity in the MCF7 cell line. Also, H. pubescens, L. frutescens and 
E. rhinocerotis extracts are the most active apoptosis inducers for the HeLa cell line. 
The CHO cell line can be regarded as a 'normal' cell line. It is also known that cancer-
derived cells such as MCF7 and HeLa are more resistant to cell death induced by 
various anti-cancer agents. This is most likely due to mutations in genes involved in 
the apoptotic pathways. For example, the MCF7 cell line in particular has been 
characterized with caspase-3 gene mutation and as a result these cells are not capable 
of activating apoptosis pathways via caspase-3 (Kurokawa et al., 1999). The major 
apoptosis pathways converge at caspase-3, highlighting the reason why the presence 
of caspase-3 is recognized as a hallmark of apoptosis. This may account for the 
increased resistance to the MCF7 cell line to apoptosis induced by the plant extract. 
The HeLa cell line is a HPV infected cell line. The HPV genes produce the E6 and E7 
proteins that bind to and inhibit p53 and Rb. Rb and p53 are important regulators of 
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the pathways (Scheffner et al., 1991). Since, the E. rhinocerotis extract exhibited 
notable pro-apoptotic activity across all three cell lines, it is a good candidate extract 
for the bio-assay guided fractionation of secondary metabolites that can induce 
apoptosis. 
 
Thus, E. rhinocerotis extract was further evaluated for specific markers of apoptosis 
such as phosphatidylserine externalization, activation of caspase-3 and DNA 
fragmentation. The study found that CHO cells treated for 6 h with the E. rhinocerotis 
extract showed externalization of phosphatidylserine and activation of caspase-3 in 71 
% and 50 % of the cells, respectively. Externalization of phosphatydilserine also 
implies the possible involvement of tBid and AIF since it is known that tBid activates 
AIF and that AIF promotes the externalization of phosphatidylserine (Wang et al., 
2007). The fact that the E. rhinocerotis extract was able to induce the activation of 
caspase-3 in CHO cells and that the MCF7 cells which are caspase-3 negative is also 
susceptible to the E. rhinocerotis extract, suggests that the secondary metabolites in 
this extract has the ability to induce both caspase-3 dependent and caspase-3 
independent pathways. The E. rhinocerotis extract also induced DNA fragmentation 
in 75 % of CHO cells treated for 48 h. The fragmentation of the genomic DNA is a 
late apoptotic event that results as a consequence of the active caspase-3 mediated 
cleavage of ICAD to activate CAD which in turn is responsible for the fragmentation 
of the genomic DNA (Sakahira et al., 1998; Zhao et al., 2001). 
 
The E. rhinocerotis extract activated several markers of apoptosis. These extracts also 
induced significant apoptosis activity in all the cell lines tested. Hence, E. 
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rhinocerotis was selected for further study to identify the secondary metabolite 
responsible for the bioactivity.  
 
 
6.3) Investigating whether the variation in bioactivity within the E. 
rhinocerotis species is associated with genetic variation 
 
It is not uncommon for plants of the same species collected from different 
geographical locations or the same geographical location at different times to display 
variation in activity (Yang and Loopstra, 2005). L. frutescens collected from different 
geographical locations demonstrated variation in pro-apoptotic activity (Chinkwo, 
2005). This prompted an investigation into whether E. rhinocerotis displays variation 
in bioactivity between isolates collected from different geographical locations. E. 
rhinocerotis was collected from various places in the Western Cape, namely 
Blaauwberg, Helderberg, Tygerberg, Kirstenbosch and Tulbagh. APOPercentageTM 
assay results indicate that the extracts of these five E. rhinocerotis samples display a 
notable variation in the degree of pro-apoptotic activity. The Kirstenbosch extract 
displayed the least activity (7%), whilst the Tulbagh extract displayed the most 
activity (71%). This is a 10 fold difference in bioactivity within the same plant 
species. The variation in the bioactivity of plant extracts within the same plant species 
from different geographical locations can be ascribed to differences in the plant 
chemistry, that is, the difference in the composition of the secondary metabolites 
present. It is possible that environmental factors can influence plant chemistry or that 
genetic event in the plant gives rise to genetic variants with different plant chemistry. 
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To investigate whether the variation in bioactivity within the E. rhinocerotis species 
is associated with genetic variation, the genetic relationships amongst the E. 
rhinocerotis samples were elucidated. Phylogenetic relationships among congeneric 
species and closely related genera in Asteraceae have been elucidated by DNA 
sequence analysis of the internal transcribed spacer (ITS) of nuclear ribosomal DNA 
(nrDNA) (Samuel et al., 2003). Thus, to determine if this variation in pro-apoptotic 
activity is a consequence of genetic variation, the ITS1 sequences of these five E. 
rhinocerotis samples were amplified and sequenced. This represents the first study 
analyzing the ITS1 sequence of E. rhinocerotis since only the trnL/F spacer of E. 
rhinocerotis has been sequenced for phylogenetic studies to date (Bayer et al., 2000). 
The sequence alignment of the five plants ITS1 region displayed 100 % to 98 % 
homology. It is worth noting that when comparing the genetic variation of the ITS1 
sequences with their corresponding levels of apoptosis activity that is; Tulbagh 
(71%), Tygerberg (57%), Helderberg (51%), Blaauwberg (42%) and Kirstenbosch 
(7%); it is found that the apoptosis activity decreases as the sequence deviates from 
the root sequence.  
 
This is still a preliminary study which may suggest a link between the genetic 
variation and apoptosis activity. However, a much bigger study is needed, along with 
a study on other Elytropappus species to establish biological significance of these 
findings. 
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6.4) The partial purification of the pro-apoptotic secondary metabolite/s 
isolated from the extract of the E. rhinocerotis plant from Tulbagh 
 
E. rhinocerotis plant material collected from Tulbagh was shown to have the highest 
pro-apoptotic activity and therefore most probably also contains more of the 
secondary metabolite/s responsible for the bioactivity. The aim therefore was to 
purify the pro-apoptotic secondary metabolite/s from the aqueous extract of E. 
rhinocerotis from Tulbagh by the bio-activity guided fractionation process and to 
attempt to characterize these secondary metabolites.  
 
The aqueous extract was used as a platform for the organic fractionation of the 
secondary metabolites.. The major activity resided in the chloroform and n-butanol 
extracts. The n-butanol fraction was further fractionated by numerous 
chromatographic separation techniques namely LCC, TLC and HPLC. The success of 
each fractionation step was ascertained by serial dilution as described by Cannell 
(Cannell, 1998). The results displayed a decrease in the percentage of bioactive units 
after each fractionation step and an increase in bioactive units concentration in the 
active fraction. This signifies the successful fractionation and purification of the pro-
apoptotic secondary metabolite(s). The E. rhinocerotis fractionation process was also 
tracked by HPLC chromatographic traces. The chromatograph traces provides a 
visual presentation of a complex mixture represented by numerous peaks on a 
chromatograph transformed into the active single peak, nB67.2.2. A single peak 
represents a single compound or a group of highly analogous compounds. Thus, the 
single peak warranted an attempt at structure determination by MS and NMR. 
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The sample was sent to the Department of Chemistry, University of Stellenbosch, for 
structure determination. The 1H, 13C, 1H-1H COSY, 1H-13C HSQC and 1H-13C HMBC 
NMR spectra was collected. Integration of these spectra revealed that many similar 
compounds were present in the HPLC sample represented as a single peak on the 
chromatograph. A structure was partially elucidated as 6-(4´-hydroxyphenyl)-2,3-
di(R)tetrahydro-4H-pyran-4-one. However, other possible clear structures could not 
be elucidated from the spectra especially as mass spectral data could not be obtained 
that could have been correlated with the NMR data.  
 
Further purification is necessary for the elucidation of two side chains. This may be 
possible by further fractionation of the active fraction by HPLC and/or 
crystallography. Once these side chains are known, the pro-apoptotic activity of this 
synthesized compound (if novel) or commercially available compound must be 
verified. 
 
 
6.5) Summary 
 
In this study nine indigenous South African plants extracts were screened for their 
ability to induce cytotoxicity and pro-apoptotic activity in the human cancer cell lines 
(MCF7 and HeLa), and the 'normal' hamster cell line (CHO). This research illustrates 
that the cytotoxicity test is not a reliable preliminary screen for anti-cancer agents, 
and it also demonstrates that the APOPercentageTM assay coupled with acquisition 
and analysis by flow cytometry provides a means to measure pro-apoptotic activity 
directly and provide accurate quantification of the degree of pro-apoptotic activity.   
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Inducers of pro-apaptotic activity are considered good lead compounds for the 
development of anti-cancer drugs. This study verified that of the nine plant extracts 
screened, C. africanum, H. pubescens, L. frutescens and E. rhinocerotis displayed the 
most notable pro-apoptotic activity and therefore this study also lends support to 
claims by traditional healers that extracts of L. frutescens and E. rhinocerotis posses 
anti-cancer properties. The E. rhinocerotis extract was selected for the purification of 
a pro-apoptotic compound/s that may serve as a lead compound or a future anti-
cancer drug. Also, C. africanum and H. pubescens are highlighted as future prospects 
for the purification process. 
 
The research described here demonstrates the efficient streamlining of the screening 
process of plant extracts for anti-cancer compound/s. It also demonstrates a successful 
bio-activity guided fractionation process. NMR spectra revealed that the single peak 
was not pure. However, a structure was partially elucidated as 6-(4´-hydroxyphenyl)-
2,3-di(R)tetrahydro-4H-pyran-4-one. In the near future, the complete elucidation of 
this pro-apoptotic compound may serve as a novel anti-cancer drug or lead 
compound. 
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